Browse 273 compounds

Well-established whitening alternative with longer-release profile (~10-16% carbamide peroxide ≈ ~3-5% H2O2); preferred for overnight tray use due to slower active release; identical efficacy outcomes vs equivalent H2O2 doses; equally safe at OTC concentrations. For Dylan-archetype CONFIRMED-IN-USE if pursuing cosmetic whitening — choose carbamide peroxide for tray-based protocols, hydrogen peroxide for strip-based.

Real evidence for hair follicle dermal papilla proliferation in vitro + decades of empirical use for eyebrow/lash/scalp hair stimulation; safe topically; very low risk profile. Limited high-quality RCTs for cosmetic use; effect is subtle and slow (3-6 months for visible results). For Dylan: optional layer if eyebrow/lash density desired; harmless to try.

Already in Dylan's V4 daily stack at 500 mg Cognizin. Best-evidenced and cleanest-safety-profile chronic choline donor for a 20yo brain-priority MMA athlete with subconcussive impact exposure — A-tier replicated trials in healthy adults (attention, working memory, processing speed) plus a large stroke-recovery evidence base, no Korean-style cardiovascular signal, and the cytidine-uridine bonus citicoline uniquely delivers makes it the ideal chronic baseline cholinergic substrate. Verdict would only change if 23andMe shows something unexpected or if a major safety signal emerges.

Largest evidence base of any sports supplement (Kreider 2017 ISSN position stand) — Dylan already runs 5-10 g/day baseline. The Forsberg 2024 (Nature Sci Reports) finding that a single 20 g dose increases brain creatine 4.4% via 31P-MRS and improves cognitive performance under sleep deprivation in 21-32 yo healthy adults opens a separate, additive use case directly relevant to Dylan's late chronotype + cognitive load + sparring nights. Verdict would only downgrade if a credible chronic safety signal emerged at sustained gram-doses (none in 30+ years of use).

Strong replicated A-tier evidence in osteoarthritis pain, depression adjunct, mild cognitive decline (PET-imaging-confirmed amyloid/tau reduction in Small 2018), and athletic recovery (DOMS, CK reduction). Dylan's V4 form (Doctor's Best Curcumin Phytosome / Meriva) has 27× bioavailability vs. unformulated curcumin — 500 mg daily ≈ ~13.5 g unformulated equivalent, in the dose range used in clinical trials. Mechanism perfectly matched to subconcussive impact + daily MMA inflammatory load. Dominant uncertainty is formulation choice (Meriva vs Theracurmin vs liposomal vs piperine), not whether to take it. Verdict would only weaken if a credible long-term safety signal emerged (none has) or if iron deficiency / gallstones developed (no current indication).

Well-established and effective for teeth whitening at cosmetic concentrations (3-6% in OTC strips/trays, 15-40% in dental office). Safe topical antiseptic. **Internal/ingested use is dangerous and unsupported** — gastric injury, oxidative stress without therapeutic benefit, embolism risk if injected. For Dylan-archetype: TOPICAL CONFIRMED-IN-USE for cosmetic teeth whitening at 3-6%; DO NOT INGEST.

Multi-decade Japanese clinical experience + emerging RCTs in EU/US show non-inferiority to fluoride for early-cavity prevention + remineralization in healthy users; particularly relevant for users wanting fluoride-free alternative; safe (it IS what teeth are made of); slightly less established than fluoride for high-cavity-risk patients but sufficient for most preventive use. For Dylan-archetype: OPTIONAL — modern toothpaste choice; not load-bearing for any priority.

Already locked in Dylan's V4 stack (Source Naturals Magtein, 3 caps/day = ~144 mg elemental Mg as L-threonate). The single magnesium form with credible evidence for raising CSF Mg in humans, with a B-tier human cognitive RCT (Liu 2016) showing memory and executive function improvement in older adults. For a 20yo brain-priority MMA athlete with chronic subconcussive impact exposure, the brain-penetrant Mg angle complements the systemic Mg from Mg glycinate (which Dylan also takes 4 tabs = 400 mg). Maintain current dosing.

Already in Dylan's V4 stack at 1200 mg/day (Swanson NAC, 2 caps). Massive A-tier evidence base — FDA-approved indication for paracetamol overdose, A-tier psychiatric (OCD, BFRB/trichotillomania), B-tier addiction + glutamate-toxicity rationale. Cheap, daily-safe, BBB-penetrant. For an MMA athlete with daily subconcussive impact, the glutamate-modulation + glutathione-precursor combination is mechanistically near-perfect — no other single supplement covers both lanes as well. Verdict would only weaken if a credible chronic-toxicity signal emerged at 1200-2400 mg/day (none currently exists after 30+ years of clinical use).

Already locked in Dylan's V4 stack (Nature's Way Rhodiola 250 mg, 1 cap/day). Best-evidenced adaptogen for fatigue resistance and mental performance under stress. Effect is modest but reliably positive for the endpoints Dylan cares about. Standard SHR-5 / Rosavin-Salidroside-standardized extracts are well-trialed. Maintain current dosing; consider bumping to 250 mg BID if morning effect not strong enough.

Best evidence-backed brain-protection compound that maps cleanly onto Dylan's MMA-subconcussive-impact thesis (CAPTAIN TBI meta-analysis effect at moderate-severe TBI, multiple stroke RCTs). Confidence is MEDIUM not HIGH because (a) athlete-prophylaxis use is extrapolation from acute injury data, (b) industry-sponsored trial bias flagged in 2025 GRADE assessment, (c) no head-to-head vs other neurotrophic peptides for sub-clinical impact load. Would upgrade to HIGH if: a true subconcussive-prophylaxis trial reads out, or if Dylan's first cycle produces clear subjective neuro-recovery signal post-spar weeks.

Best-evidenced eugeroic with 25+ years of safety data, low tolerance, low abuse liability, cheap gray-market sourcing. Confidence would only drop if Dylan develops rash (SJS), persistent insomnia, or unmanageable anxiety in first 8 weeks.

Reasonable A/B-test candidate vs modafinil for Dylan but the longer late-day plasma tail and 3-4hr later Tmax make it riskier for a late chronotype migrating to midnight bedtime; modafinil 100 mg AM remains the safer daily-driver default. Verdict would shift to OPTIONAL-ADD if A/B test shows modafinil insufficient duration past 3 PM, or to SKIP-FOR-NOW if armodafinil pushes sleep onset past 1 AM in week 8-12 trial.

Cheap, daily-safe, A-tier mechanism + skin/eye RCTs, B-tier exercise recovery, mechanistically supportive for mitochondrial protection in a brain-priority MMA athlete; near-zero downside; perfect pairing with V4 fish oil. Verdict would only weaken if a clean direct cognitive RCT in young adults came back null AND a price spike happened.

For Dylan's specific cubital tunnel / ulnar nerve compression — peripheral nerve regeneration is one of the most robust BPC-157 animal data sets (sciatic crush, transection, spinal cord), mechanism is aligned (VEGFR2 angiogenesis + Schwann-cell support + anti-inflammatory at compression site), peptide-vendor sourcing is solvable, side-effect profile in 20+ years of rat data is benign, and a 4-8 week localized-injection trial is reversible. Confidence is MEDIUM not HIGH because (a) ZERO Phase 3 human RCTs exist for any indication, (b) >80% of evidence base is from a single Croatian lab (Sikiric/Seiwerth, Zagreb) with open 2024-2025 academic dispute about confirmation bias and lack of independent replication, (c) FDA 2024 prohibition flags "potential safety concerns" without specifying them, and (d) no published protocol exists for cubital tunnel specifically — Dylan's protocol would be extrapolated from sciatic-nerve rat data + biohacker community consensus. Would upgrade to HIGH if (a) an independent Phase 2 nerve-injury RCT replicates the Croatian results, (b) Dylan runs a 4-week local-injection trial near both elbows and sees objective symptom reduction (tingling threshold, Tinel's sign at cubital tunnel), or (c) an orthopedic sports-medicine systematic review reports positive human data. Would downgrade to OPTIONAL-ADD if FDA issues specifics on the 2024 safety concerns or if cancer-angiogenesis signal emerges in any human cohort.

Mechanism is unusual and attractive (synthesis upregulation, not release/reuptake), Russian clinical signal is strong (n=728 asthenia trial + military/cosmonaut deployment), and the daily-safe / no-tolerance / no-withdrawal profile fits Dylan's brief better than almost any other DA-active compound. Confidence is MEDIUM not HIGH because (a) all major human evidence is single-source Russian (Pharmstandard / Seredenin lab), (b) zero independent Western RCTs, (c) the 728-pt trial was open-label and uncontrolled, (d) supply-chain quality is now degraded since Pharmstandard discontinued the branded product. What would change the verdict: independent Western RCT or replication, OR a clean stack run showing measurable cognitive/fatigue benefit at 4-6 weeks.

Best-evidenced cognitive enhancer + ergogenic on the planet, trivial sourcing, and Dylan's zero-baseline = maximum responder window. Cycle 2-4 days/week + theanine pairing + AM-only dosing preserves responsiveness and protects late-chronotype sleep migration. Confidence drops only if Dylan is CYP1A2 CC (slow metabolizer) per pending 23andMe — would shift to once-or-twice-weekly PRN.

Gordji-Nejad 2024 (Sci Rep) is a clean RCT in 21-32 yo healthy adults showing a single 20 g dose produces measurable brain creatine increase via 31P-MRS AND cognitive performance rescue under 21 hr sleep deprivation. Mechanism is well-grounded (cerebral ATP buffering during metabolic stress). Effect size modest in absolute terms but the demographic + sleep-deprivation context maps directly to Dylan's late chronotype + sparring + cognitive workload profile. PRN protocol (1-3×/month max) sits on top of his existing 5-10 g/day baseline without replacing it. Verdict downgrades only if (a) replication fails, or (b) chronic high-dose data emerges showing accumulation harm. Verdict upgrades to STRONG-CANDIDATE-DAILY if 10 g/day chronic brain-saturation data accumulates and Dylan wants the steady-state version rather than acute pre-stress.

A-tier evidence for cleaner cognition when paired with caffeine; A-tier subjective sleep onset support; B-tier acute anxiolytic. Cheap, daily-safe, minimal tolerance, stack-clean with everything in V4. Already in V4 at Suntheanine 200 mg/day. Verdict would only change if a credible chronic-toxicity signal emerged (none does) or if the 2025 sleep meta-analysis "subjective-only, not objective" finding hardens into "placebo-equivalent on PSG" — at which point it stays A-tier for caffeine pairing but becomes B-tier (not A) for sleep onset.

A-tier evidence for sleep onset latency reduction at 1 g+ doses with the proper timing (empty stomach, 30-60 min pre-bed); cheap; clean side effect profile; pharmacologically more relevant than glycine for a late-chronotype migrating earlier (it actually feeds the melatonin pathway, glycine doesn't). Would shift to PRIMARY-PICK if Dylan's bloodwork shows low ferritin/B6/Mg (which would otherwise bottleneck conversion).

For Dylan's specific use case — late-chronotype migration from 2-3 AM toward midnight bedtime — low-dose (0.3-0.5 mg) early-evening melatonin is one of the few interventions with A-tier evidence directly on his actual problem (delayed sleep-wake phase disorder, DSWPD). The phase-advance application is mechanism-aligned, evidence-supported (Brzezinski/Zhdanova MIT physiological-dose meta-analyses, AASM 2015/2024 DSWPD clinical practice guideline), cheap ($5-15/mo), low-risk at correct dose/timing, and complementary to his V4 magnesium glycinate + magtein stack. The verdict is HIGH-confidence for phase-shift use AND explicitly NOT a sleep-onset hypnotic recommendation — high doses (3-10 mg) at bedtime are both unnecessary and counterproductive for his chronotype problem. Verdict would shift to PRIMARY-PICK only if behavioral phase-advance proves insufficient at week 4-6 and Dylan formally adds it; would shift toward WATCH-LIST only if he develops a measurable HPG-axis concern (theoretical, very unlikely at these doses) or finds it produces morning grogginess despite microdose protocol.

Plausibly a longer-acting, more convenient Semax; mechanism extrapolated from parent compound; PK numbers and "3-5x potency" claims are vendor-marketing not peer-reviewed; only meaningful if vendor identity/COA can be verified — otherwise it's just expensive Semax (or worse, regular Semax mislabeled). Promote to higher confidence if a verified COA + 4-week self-trial replicates Semax effects at lower mcg with longer duration.

Clean stim-class racetam with measurable cognitive + physical performance benefit, well-fit to Dylan's high-cognitive-load business days and pre-MMA-training pulses. Verdict is PRN-only (not daily) because tolerance reliably builds in 1-2 weeks of daily use — this is the load-bearing limit. Confidence is MEDIUM-HIGH not HIGH because the entire human evidence base is single-source Russian (Savchenko 99-pt encephalopathy trial; ~400-pt stroke trial citation, but primary-source attribution is murky), zero independent Western RCTs exist, and the encyclopedia/secondary-source claim of "400-patient double-blind stroke trial" appears to conflate multiple smaller trials — see Open questions. What would change the verdict: independent Western RCT, better characterized tolerance kinetics in humans, or a clean Dylan A/B against pramiracetam at matched cost.

Best-in-class non-sedating anxiolytic for Dylan's pre-sparring / pre-presentation / pre-call anxiety with no tolerance, no dependence, and benzodiazepine-comparable acute efficacy in Russian RCTs. Mechanism is well-characterized and multi-modal; safety record across 17+ years of Russian Rx use is exceptional. Confidence is MEDIUM-HIGH not HIGH because (a) all RCT-quality human data is Russian (Zozulya 2008 vs medazepam, Kost 2024 alcohol-withdrawal), (b) Western replication is thin, (c) effect size in already-low-anxiety baseline is uncertain. Verdict would upgrade to PRIMARY-PICK (PRN tier) only if Dylan's first 4-week PRN trial shows clear pre-event benefit; would downgrade only if nasal irritation persists past adaptation window or if the anxiolytic effect is sub-noticeable.

Verdict applies to LOW ORAL (1-2.5 mg) tier only — strong mechanistic + animal-longevity case + clean human safety at this dose, but direct healthy-young-adult cognitive evidence is thin. Emsam tiers separately verdicted in body. Would upgrade to PRIMARY-PICK if 23andMe shows DRD2 Taq1A A1 carrier or low-DA-tone genotype where preservation matters more; would downgrade to OPTIONAL-ADD if baseline mood + drive already strong without it.

Excellent fit for Dylan's brain-priority + MMA-subconcussive context (neurotrophic + dopaminergic without amphetamine-class downsides); main caveat is that Adamax appears to be the same mechanism with better duration and BBB profile, so Semax is the explicit tier-1 backup if Adamax sourcing slips. Verdict would upgrade to PRIMARY-PICK only if Adamax sourcing fails.

Cheap, safe, broad mechanistic coverage relevant to MMA cardio + impact recovery + sleep. Verdict holds even if 2025 longevity reanalysis is correct — cardiovascular and exercise evidence stand independent of the contested aging-driver hypothesis. Would only downgrade if a credible chronic-toxicity signal emerges at 1-3g doses (none currently exists).

Strong preclinical (rodent + equine) and mechanistic case for cubital tunnel + general MMA recovery, classic pairing with BPC-157 covers complementary repair pathways (BPC-157 = VEGFR2/NO/local; TB-500 = G-actin/cell-migration/systemic). Confidence is MEDIUM not HIGH because: (a) the human evidence is thin — RGN-259 ophthalmic Phase 3 (full TB-4 protein, not the LKKTETQ fragment) MISSED primary endpoint in 2024 SEER-3 European trial, RGN-352 cardiac was clinical-hold-stalled since 2011; (b) most "TB-500" community data is racehorse-derived; (c) March 2024 paper suggests the active wound-healing metabolite is Ac-LKKTE (5-AA), not the LKKTETQ heptapeptide vendors sell — opening a real possibility that injected TB-500 only works via metabolic conversion; (d) theoretical cancer-promotion concern (TB-4 overexpressed in pancreatic, NSCLC, RCC, colorectal cancers — causation unresolved) flags a non-zero risk for any user with cancer family history; (e) human data confidence would jump if RGN-259 US Phase 3 reads positive or any sport-medicine trial publishes. Verdict would downgrade to OPTIONAL-ADD if cancer-promotion causation gets confirmed, or upgrade to PRIMARY-PICK for cubital tunnel if a peripheral-nerve RCT reads positive in humans.

For Dylan's MMA subconcussive prophylaxis use case, mechanism is highly aligned (oral analog of cerebrolysin's neurotrophic logic — multi-target neuroprotection, mitochondrial preservation, anti-neuroinflammatory) but evidence base is **acute ischemic stroke and post-stroke cognitive impairment in Chinese populations**, not subconcussive impact in young healthy athletes. TBI rodent data is positive but no human TBI RCT exists. Hepatotoxicity signal (ALT elevation 1.4-17.5% in trials) is real but manageable with monitoring + NAC (already in V4). Verdict would upgrade to STRONG-CANDIDATE if (a) any human TBI/concussion RCT reads out positive, (b) CSPC's US Phase 3 program publishes a non-Chinese cohort, or (c) a head-to-head against cerebrolysin shows non-inferiority. For now: cheaper oral adjunct to cerebrolysin worth a single 90-day cycle when the V5 stack is otherwise stable.

Strong rodent evidence for BDNF-pathway activation, neuroprotection, and TBI/depression models — but human data is essentially absent and oral bioavailability is poor (~5%). Speculative pick for Dylan's brain-protection thesis; 7,8-DHF prodrug R-13 may be the path forward.

Real but mild "cleaner caffeine" energy + mitochondrial insurance for a 20yo athlete; the TMAO/cardiovascular concern (>30-fold rise on 1.5 g/day) is the only thing keeping it out of STRONG-CANDIDATE — cycling or stacking with TMAO-mitigating fiber/probiotics restores the case.

For Dylan-archetype, the compound stacks safely with V4/V5 and offers a plausible 4-in-1 angle (mild calm, pre-workout pump, neuropathic-pain ceiling, stim-tolerance hedge) at low cost; verdict would upgrade to STRONG-CANDIDATE if a single mechanism (e.g., elbow neuropathic pain, modafinil tolerance prevention) becomes dominant in his use case, or downgrade to SKIP-FOR-NOW if pill burden becomes a problem and no subjective signal emerges in 4-6 week trial.

Real, fast-onset acute cognitive enhancement (60-90 min) and replicated growth-hormone + power-output bump pre-workout, but the 2021 Korean nationwide cohort signal (12 M people, dose-dependent stroke aHR 1.43-1.46) plus the mechanistic TMAO-atherogenesis pathway means chronic high-dose daily use is not free; for Dylan, citicoline already covers chronic choline so alpha-GPC is best as PRN pre-task / pre-workout (300-600 mg) rather than daily.

Different mechanistic flavor from pramiracetam (mood-bright + creativity + mild anxiolysis vs cognitive sharpness) backed by a B-tier 1991 EU placebo-controlled SDAT trial (n=109, 1500 mg/day, 6 mo, 12-35% SCAG improvement vs 9-19% placebo decline) and Japan post-stroke depression/anxiety use through the 1990s — but healthy-adult cognitive enhancement evidence is thin (one Baylor crossover) and a confirmatory placebo-controlled trial in Japan failed, prompting market withdrawal there. For Dylan-archetype: defensible PRN tool for mood/creativity-flavored sessions where pramiracetam isn't the right fit; requires fat for absorption, doesn't add value chronically given the ~30 min parent-compound half-life, and overlaps mechanistically with citicoline/V4 stack on the cholinergic side. Verdict would upgrade to STRONG-CANDIDATE only if a modern healthy-adult RCT replicated the EU SDAT cognitive signal in cognitively-intact subjects; would downgrade to SKIP-FOR-NOW if any signal of long-term receptor desensitization / cognitive blunting emerged or if Dylan reports paradoxical anxiety on trial dose.

Strong mechanistic story (CD38/NAD+, GABA, senomorphic) but bioavailability is ~30% with rapid clearance — most users at 50 mg likely under-dose for systemic effects. Cheap insurance bet; would upgrade to STRONG-CANDIDATE if liposomal form used + bloodwork shows estradiol baseline isn't already low.

Solid evidence for anxiety reduction and cortisol attenuation in stress-prone populations; testosterone effect modest and most pronounced in older or stressed men, less impressive in young athletes. For Dylan (20yo, no anxiety indication, V4 already includes rhodiola for adaptogenic coverage) — low priority but reasonable add. STRONG-CANDIDATE for stress-prone or anxiety-prone archetypes. Stack-conflict caution: ashwagandha can increase thyroid hormone levels — monitor if hyperthyroid risk.

KSM-66 is the best-trialed standardized ashwagandha extract for testosterone, cortisol, and athletic performance endpoints. For Dylan, low-priority add given V4 already includes rhodiola for adaptogenic coverage; STRONG-CANDIDATE for stress-prone, athletic, or T-focused archetypes. Verdict would upgrade to STRONG-CANDIDATE if Dylan's June bloodwork shows elevated cortisol or low-normal testosterone for age. See parent ashwagandha.md for full pharmacology.

Sensoril is the optimal ashwagandha extract for sleep-onset and anxiolytic endpoints due to its higher withanolide concentration and root + leaf composition. For Dylan, OPTIONAL-ADD low priority — V4 sleep stack (Magtein, glycine→tryptophan, magnesium glycinate) already addresses sleep architecture. STRONG-CANDIDATE for sleep-disordered, anxiety-prone archetypes. KSM-66 likely better choice for Dylan's profile if any ashwagandha is added (more pro-energy, fits AM dosing).

A-tier replicated RCT evidence for memory consolidation + delayed recall in healthy adults, but the effect is small-medium and requires 8-12 weeks of daily dosing before benefit emerges; sedation in ~5-15% users is the live concern for an MMA athlete with daily sparring; worth a 12-week trial only if Dylan can commit to the full build-up window.

Solid evidence for mood/motivation/anhedonia in target populations and clean stim-like profile without amphetamine harshness — but Dylan's daily subconcussive head-impact exposure (10+ hr/wk MMA + sparring) is the exact pattern FDA labeling and TBI literature flag for elevated seizure-threshold risk. Worth holding until baseline (modafinil + bromantane + selegiline) lands; revisit only if anhedonia/motivation persists, and only via XL formulation at 150 mg max with prescriber knowing the head-impact context.

A-tier preclinical neuroprotection across multiple labs and models (5xFAD AD, Parkinson's, ischemia, subarachnoid hemorrhage), elegant proelectrophilic mechanism that activates only in damaged tissue, FDA GRAS, very few side effects at supplement doses, cheap (~$15-30/mo), and stack-clean with V4 curcumin + V5 astaxanthin + NAC. **The catch: zero published human cognitive RCTs exist.** Lipton's 2025 diAcCA paper from Scripps is the highest-profile recent translational push, but human trials haven't started. For Dylan: cheap insurance compatible with the MMA subconcussive-impact thesis, but should be sized as a low-conviction additive layer behind astaxanthin/cerebrolysin/idebenone, not as a primary brain-protection move. Verdict would upgrade to STRONG-CANDIDATE if (a) diAcCA enters and clears Phase 1, (b) NRF2 wild-type genotype confirmed in Dylan, or (c) a clean human cognitive/oxidative-stress RCT lands positive. Would downgrade to SKIP-FOR-NOW if a meaningful hepatotoxicity signal emerges in healthy long-term users at >200 mg/day.

Solid pre-workout vasodilator with replicated meta-analysis support for reduced fatigue + reps; PRN before hard MMA sessions makes sense, daily dosing unnecessary.

Mechanism is unique among racetams (HACU enhancement via CHT1 trafficking, not receptor modulation) and the visual-perception subjective effect is genuinely interesting and reproducibly reported, but human evidence is one mixed Phase 2a depression trial (BrainCells 2008-2010, BCI-540, missed primary endpoint with subgroup signal in MDD+GAD) and a single n=1 case study; cognitive enhancement evidence in healthy adults is anecdotal-only. Verdict would upgrade to STRONG-CANDIDATE PRN if a fresh trial replicated the MDD+GAD signal or if Dylan finds the visual/cognitive effect reproducible in a self-trial; downgrade to SKIP-FOR-NOW if pramiracetam already covers his cholinergic-racetam slot without redundancy.

Real adaptogenic + immune-modulation evidence (Davydov 2000 review; Hartz 2004 RCT for chronic fatigue), but the modern Western evidence base is thin and overshadowed by rhodiola for the same use cases. For Dylan, low-priority OPTIONAL-ADD — V4 already covers adaptogenic ground with rhodiola. Verdict would upgrade to STRONG-CANDIDATE for immune-frequency-illness archetype or chronic fatigue presentations; remains OPTIONAL-ADD low for cognitive optimization in healthy young adults.

Mechanism is genuinely interesting (slow-acting glutamate-system rebalancer rather than acute stimulant or GABA agonist), the Nippon Shinyaku safety record is long, and it has the only credible pediatric pivotal-track development of any racetam — but the clinical efficacy story is mixed (one positive open-label adolescent ADHD signal in mGluR-mutation carriers, one fully negative randomized Phase 2 in unselected ADHD, one underpowered signal-finding crossover in 22q11.2DS that missed p<0.05). For Dylan-archetype with no mGluR mutation phenotype and no anxiety pathology, the upside ceiling is "subtle anxiolytic + mild cognitive smoothing on a long-acting GABA-B/mGluR axis," which does not displace anything in V4/V5. Verdict would upgrade to STRONG-CANDIDATE if Nobias Phase 2b/3 hits in 22q11.2DS AND independent biohacker corpus replicates an anxiolytic effect at 5–30 mg in non-mutation-carriers; would downgrade to SKIP-FOR-NOW if any further controlled trial fails or if the GABA-B upregulation rebound profile turns out to mirror phenibut withdrawal in chronic-dosing biohackers.

GHK-Cu is the rare compound where topical use has 50+ years of replicated mechanism + clinical evidence (A-tier for skin aging, hair growth, wound healing) while injectable systemic use is biohacker-extrapolation from topical mechanism with thin direct evidence and theoretical copper-accumulation concerns. For Dylan: topical use is a real option for nose dermatitis + as connective-tissue insurance; SC for cognition is wrong-tool (Cerebrolysin / Semax / NASA already cover that lane with stronger evidence). Verdict would upgrade for SC if (a) human RCT data on systemic GHK-Cu lands, (b) Dylan develops a specific connective-tissue indication that GHK-Cu hits better than BPC-157 + TB-500.

GLOW is a real, sensible 3-peptide combo for skin + soft-tissue regeneration with reasonable mechanistic cohesion (all three are upregulators of collagen/repair pathways). For Dylan, two of three components are already in pipeline for cubital tunnel — so GLOW-as-such is a packaging decision, not a new vector. Confidence is MEDIUM because (a) fixed-blend products often deliver components outside individual therapeutic ranges (pep-pedia explicitly flags this), (b) no human RCTs on the blend itself, (c) Dylan's primary skin issues (perioral dermatitis + tinea cruris) are better addressed by topical clotrimazole + GHK-Cu than by injectable blend. Verdict would upgrade to OPTIONAL-ADD if Dylan adds dedicated aesthetic/anti-aging cycle, or if skin issues persist after V4 topicals fail.

Sleep evidence at 3 g pre-bed is real but thin (two small Ajinomoto-funded trials, no independent replication, modest effect sizes on subjective metrics). NMDA glycine-site mechanism is well-established but generic — substrate is not rate-limiting in healthy adults. Cheap and safe enough that it's defensible as a daily-driver, but for Dylan specifically the V5 plan correctly flags it for replacement with l-tryptophan, which has stronger evidence and better mechanism-fit for late-chronotype melatonin pathway support. Verdict would shift to STRONG-CANDIDATE if (a) independent non-Ajinomoto replication of the 3 g sleep effect appeared, or (b) Dylan's bloodwork showed kynurenine-shunt reasons l-tryptophan won't work. Verdict would shift to SKIP if a credible safety signal emerged at 3 g (none currently exists).

Chinese AD trials (Xu 1995, Zhang 2002, Cochrane 2008 pooled) are robust at 200-400 mcg/day with replicated cognitive benefit on MMSE/ADAS-Cog/HDS; healthy adolescent Chinese trials (Sun 1999) showed memory benefit; healthy young adult Western data is thin. For Dylan at 20 with citicoline 500 mg already daily, stacking AChE inhibition on top of choline supply is mechanistically sound for *acute task booster* but risks chronic post-synaptic muscarinic/nicotinic downregulation if used daily — cycling 4 weeks on / 1-2 weeks off is non-negotiable. Verdict would shift to STRONG-CANDIDATE if APOE ε4+ on 23andMe (June 2026); would shift to SKIP-FOR-NOW if cholinergic dysphoria emerges in trial.

A-tier evidence in LHON only; B-tier in DMD respiratory function and Friedreich's cardiac hypertrophy reduction; C-tier in MCI/post-stroke cognitive impairment (recent 2024-2025 Chinese trials look real but are non-Western, often single-arm, and cognitive evidence in healthy young adults is essentially absent). Mechanism (BBB-crossing electron carrier + lipid-membrane antioxidant) is highly compatible with Dylan's brain-priority + MMA mitochondrial-load thesis, and stack-safe with V4/V5 (especially astaxanthin and ALCAR). But for Dylan's age/health bracket, ALCAR + astaxanthin already cover most of the same mitochondrial-protection ground at lower cost and with cleaner evidence. Verdict would upgrade to STRONG-CANDIDATE if (a) a clean young-adult cognitive RCT lands positive, (b) a contact-sport TBI/subconcussive-impact biomarker study reads out positive, or (c) NQO1-genotype data places Dylan in a likely-responder category. Verdict would downgrade to SKIP-FOR-NOW if a hepatotoxicity signal emerges in healthy long-term users or if cost stays >$60/mo for evidence this thin in his demographic.

KPV is the C-terminal tripeptide of α-MSH and one of the rare oral-bioavailable peptides (survives gut peptidases due to small size + Pro residue), with B-tier human evidence in ulcerative colitis (Pliva BCT-1 / PL-14736 Phase 2 in early 2000s) and consistent A-tier animal data across colitis, contact dermatitis, asthma, and arthritis models — all converging on NF-κB inhibition as the core mechanism. For Dylan specifically: useful where his V4 stack hasn't fully resolved nose dermatitis (perioral pattern) and tinea cruris co-inflammation, plus theoretical fit for post-sparring gut barrier stress and skin lesion healing on the same KLOW-stack lane as GHK-Cu. Verdict is OPTIONAL-ADD not STRONG because (a) no human RCT exists outside the IBD use case, (b) the perioral dermatitis + tinea cruris combo is more directly addressed by the V4 clotrimazole + behavioral fixes Dylan already has, and (c) BPC-157 already covers gut + tissue healing in Dylan's pipeline. Would upgrade to STRONG-CANDIDATE if (a) Dylan's skin issues persist past 8 weeks of clotrimazole + behavioral fixes, (b) a flare of post-sparring GI symptoms emerges, or (c) a combat-sport-relevant chronic-inflammation indication develops. Would downgrade if Dylan's skin clears on V4 baseline alone.

Well-characterized compound; effect-size honestly small in healthy adults. Strong evidence in catabolic/ICU/burn populations does not transfer to MMA athletes outside extreme overreaching states. Useful adjunct for gut/immune insurance during high training load; cognitive benefit weak. Cheap enough to try; not a primary lever. Would upgrade to STRONG-CANDIDATE if Dylan develops persistent gut issues, frequent URTI, or enters a documented overtraining/illness window.

A-tier evidence for stress-condition cognitive rescue (military training, cold, sleep deprivation) and B-tier for sustained working-memory under cognitive load — but no meaningful effect at baseline in non-depleted neurons. For Dylan-archetype, valid as PRN tool pre-sparring / pre-cognitive-load-day / pre-modafinil-washout-day; not a daily-core candidate. Cheap and safe. Verdict would upgrade to STRONG-CANDIDATE if Dylan moves to chronically sleep-deprived training blocks or if 23andMe shows COMT Val/Val (faster DA clearance, plausibly more responsive to substrate loading); would downgrade to SKIP-FOR-NOW only if subjective signal stays absent across ≥3 stressor exposures.

Real molecular mechanism (erinacine A NGF stimulation in vitro is well-replicated) but the gap between bench data and clinical effect in healthy young adults is significant. The single best human trial (Mori 2009) was Japanese MCI patients, not healthy 20yos. Cheap, safe, and has plausible upside for Dylan's brain-priority/MMA brief, but it's clearly second-tier next to the Russian peptide layer (Semax/NASA/Adamax/Bromantane) for actual NGF/BDNF effect. Verdict would upgrade to STRONG-CANDIDATE if (a) a healthy-adult RCT replicates the Mori signal, OR (b) a head-to-head vs. Semax shows comparable subjective benefit. Would downgrade to SKIP if Dylan reports the (anecdotal) genital-numbness side effect.

Real mechanistic and epidemiological signal for low-dose lithium as a brain-protective micronutrient (GSK-3β / BDNF / tau / hippocampal volume), with the only RCT-grade human cognitive data being Nunes 2013 (Alzheimer microdose) and Marshall-style microdose follow-ups. Direct evidence in healthy young adults is thin; the most Dylan-relevant data is Pacholko 2024 (rat mTBI) plus the Schrauzer/Sugawara/Kessing population-water-lithium series. Verdict would upgrade to STRONG-CANDIDATE if (a) Pacholko-type findings replicate in a human concussion cohort, (b) a baseline-low serum lithium is documented for Dylan, or (c) longer-term hippocampal-volume preservation data emerges at OTC doses. Verdict would downgrade to SKIP-FOR-NOW if any unexpected thyroid/renal signal appears at 5-10 mg elemental Li in healthy young adults — which is not currently in the literature.

For Dylan-archetype, memantine is a tolerance-modulation hedge — useful only IF chronic stimulant tolerance becomes a real problem (which is unlikely on modafinil-only and unproven on bromantane). Brain-priority allows it because memantine is uniquely "physiology-sparing" among NMDA antagonists, but the human evidence for stim-tolerance prevention is anecdote + animal data, not clinical-grade. Verdict would upgrade to OPTIONAL-ADD if Dylan transitions to a classical stimulant (Vyvanse/Focalin/methamphetamine) where dopamine receptor downregulation is real, or if a TBI/concussion event from sparring creates an acute neuroprotection rationale. Verdict would drop to SKIP-FOR-NOW if Dylan reports cognitive blunting at 5-10 mg/day during a trial, or if dissociative threshold is reached at lower-than-expected doses suggesting individual hypersensitivity.

A-tier evidence only for the rescue indications (methemoglobinemia, sepsis vasoplegia, ifosfamide encephalopathy) — none of which Dylan needs. B-tier for cognitive/memory enhancement (Rodriguez 2016 single-dose fMRI study; Telch arachnophobia fear-extinction trial) and for TBI animal models (Watts 2017). C-tier for healthy young-adult cognitive enhancement — biohacker hype massively outruns the evidence. The mechanism IS genuinely unique (no other mitochondrial-bypass + MAO-A combination at this price) and IS plausibly relevant to Dylan's subconcussive-impact thesis, but the dosing window is narrow (biphasic — wrong dose flips it pro-oxidant) and the SSRI-class drug-interaction surface is real. **Verdict would upgrade to STRONG-CANDIDATE if (a) a healthy-young-adult cognitive RCT replicates Rodriguez 2016 cleanly, or (b) a contact-sport TBI biomarker study reads out positive at low dose.** Would downgrade to SKIP-FOR-NOW if Dylan adds bupropion or any serotonergic per V5 contingency, or if the gray-market USP supply chain shows contamination signal.

Genuinely interesting endogenous-peptide mechanism with strong rodent A-tier evidence (insulin sensitivity, exercise capacity 2× in 22-mo mice, healthspan + trend toward lifespan extension), but **zero published human RCT efficacy data on native MOTS-c as of May 2026**. The most advanced human trial — MOTS-c analog CB4211 Phase 1a/1b (CohBar, 2021) — completed safely with positive ALT/AST/glucose biomarker signals, but CohBar abandoned the program in 2023 (formulation issues, company merged into TuHURA). A **Phase 2a native-MOTS-c study (NCT07505745, "MOTS-MET", Hudson Biotech, 120 prediabetics, 12 weeks SC daily)** started recruiting Feb 2026 — readout est. May 2028. For Dylan: exercise-mimetic claim is interesting for MMA cardio/recovery but **(a) WADA-banned (would matter if he goes sanctioned), (b) evidence is preclinical, (c) higher-yield levers exist** (sleep, creatine, beta-alanine, actual training). Would upgrade to STRONG-CANDIDATE if MOTS-MET reads out positive on insulin sensitivity + safety, OR if Dylan's first 60-day cycle produces a clear cardio/recovery signal post-bloodwork (June 2026).

Marketing claims of superior bioavailability are largely refuted by pharmacokinetic data showing low systemic tyrosine yield; plain L-tyrosine is cheaper and better-evidenced. Keep as minor option only if GI tolerance to L-tyrosine is poor.

At 20yo Dylan's baseline NAD+ is already near-peak. The age-decline thesis itself is contested (Brenner: blood NAD+ doesn't clearly drop with age; tissue NAD+ varies). Human trials reliably raise blood NAD+ ~130-150% but functional endpoints (cognition, muscle, lifespan) remain mixed-to-null. For Dylan, apigenin (CD38 inhibition — preserves existing NAD+) is more cost-effective than precursor supplementation. Verdict would change to STRONG-CANDIDATE if (a) bloodwork shows low NAD+ at his age, (b) a definitive A-tier human cognitive/performance trial lands, or (c) Dylan crosses 35-40.

For Dylan-archetype (20yo, no autoimmune dx, no addiction, no chronic pain) LDN is interesting but not yet justified — the strong evidence is in fibromyalgia/MS/Crohn's/long COVID, not in healthy MMA athletes. Becomes OPTIONAL-ADD if a chronic inflammation signal emerges (persistent post-impact CNS inflammation, training-load fatigue not resolving with V4/V5 baseline, or any autoimmune flag in June bloodwork). Standard 50 mg dose is irrelevant to him (no AUD/OUD). What would change verdict to OPTIONAL-ADD: (a) bloodwork showing elevated hsCRP/IL-6 not resolving on V4 anti-inflammatory layer, (b) subjective brain-fog/recovery plateau after 8-12 weeks of V5, OR (c) any autoimmune marker in 23andMe → bloodwork pipeline.

Mechanistically interesting "anti-apathy + anxiolytic-flavored racetam" with one positive Phase 2 apathy substudy (Robinson 2009, post-stroke depression cohort, n=70, 900mg arm) — but the headline post-stroke depression Phase 2 (Robinson 2008, n=159) MISSED its primary endpoint, the 2016 Starkstein replication for post-stroke apathy was underpowered (n=13) and negative, Daiichi withdrew its Japanese NDA in 2002 for insufficient efficacy, and there are zero healthy-young-adult cognitive-enhancement RCTs. For Dylan-archetype: rarely the right call vs better-evidenced racetams (pramiracetam for memory/focus, aniracetam for mood-anxiolytic flavor); only consider if specifically chasing the apathy/motivation phenotype and other Russian dopaminergics (bromantane, sulbutiamine) under-deliver. Confidence would jump to MEDIUM only if a healthy-adult cognitive-enhancement RCT replicates the apathy-Scale signal in a non-stroke population.

Cheap, exceptionally safe, and a genuine NAD+ precursor — but at supplemental doses (50-500 mg) the systemic NAD+ effect is real but modest and largely overlaps with what NMN/NR deliver. The "high-dose nootropic" 500-1500 mg/day protocol has scattered cognitive and skin/longevity case data but no large RCT. For Dylan, a low-dose B3 inclusion (50-100 mg) is reasonable insurance; the 1500 mg high-dose protocol is not justified by current evidence.

Lightest-touch racetam with documented "logical/analytical/energetic" subjective flavor, useful PRN for coding-heavy days, but the most rigorous recent evidence (2023 Korean phase IV n=500, 2024 Frontiers Bayesian meta-analysis) is unimpressive — the encyclopedia's "B-tier vascular dementia" framing leans on 1980s-90s Italian trials that don't replicate at modern methodological standard. Verdict would upgrade to STRONG-CANDIDATE if Dylan runs a clean A/B test and finds it actually delivers the analytical lift; would downgrade to SKIP if it feels equivalent to placebo on his coding throughput.

Better cognitive evidence base than eleuthero; multiple A-tier human cognitive RCTs (Reay 2005/2006, Scholey 2010 Cereboost). Korean Red Ginseng in particular has solid evidence for attention and working memory in healthy adults. For Dylan, OPTIONAL-ADD — V4 covers cognitive ground but Panax is mechanistically distinct from rhodiola/citicoline; could add as PRN cognitive boost. STRONG-CANDIDATE for executive maintenance and 50+ archetypes. Modest stim-like effect requires AM dosing.

Small but converging RCT signal for caffeine-equivalent cognitive benefit with cleaner cardiovascular + sleep profile, plus shorter half-life that suits Dylan's late-chronotype migration. Confidence is MEDIUM (not HIGH) because long-term safety data is essentially absent (ingredient launched 2022), the RCT base is single-sponsor (Compound Solutions / Jagim/Kreider/Arent group), and caffeine + theanine likely matches paraxanthine's clean profile at a fraction of the cost. Would upgrade to STRONG-CANDIDATE if independent (non-Compound-Solutions-funded) RCTs replicate the cleaner-than-caffeine claim and 12-month safety data lands.

Cheap, fast-acting, and the molecule that famously gives chocolate its trace stimulant signature — but the 5-15 min half-life means standalone PEA is essentially useless without a MAO-B inhibitor (selegiline) or a competitive MAO-B substrate (hordenine) to extend it. As a PRN tool stacked with hordenine it is mildly interesting; as a standalone supplement it is mostly placebo. CRITICAL: distinct from palmitoylethanolamide (also abbreviated PEA), which is the anti-inflammatory PEA-Ultra product.

Cheap, daily-safe, non-addictive Russian-Rx anxiolytic with B-tier evidence for cerebrovascular insufficiency, anxiety, and migraine prophylaxis — narrow PRN niche for stress days as a tianeptine-tier alternative without the dependence profile. Verdict would upgrade to STRONG-CANDIDATE if a Western-quality RCT replicated the 2024 Danilov cerebral-ischemia data, or if Dylan develops a specific anxiety phenotype that responds; would downgrade to SKIP-FOR-NOW if no subjective signal emerges in a 2-3 week PRN trial or if pill burden becomes an issue.

Multiple A-tier indications (chronic venous insufficiency Cochrane meta, allergic rhinitis, ADHD adjunct Trebatická 2006, vascular endothelial function Liu 2013, ED Stanislavov 2003) with broad safety margin and clean mechanism. For Dylan's archetype (20yo MMA, brain + vascular + recovery focus), the mechanism is supportive — endothelial NO, anti-inflammatory, mild antiplatelet, collagen support — but the V4/V5 stack already has overlapping antioxidant + anti-inflammatory coverage from astaxanthin (membrane), curcumin (NF-κB/COX), NAC (glutathione), apigenin (flavonoid). Pine bark is a credible LATERAL move, not a missing pillar. Verdict would strengthen if Dylan develops vascular complaints (cold extremities, ED, varicose tendency), allergic rhinitis, or wants ADHD-adjunct support — otherwise it sits in the "fine to add, not required" tier behind the V4/V5 antioxidant quartet.

Parent racetam with strong A-tier evidence for cortical myoclonus, post-stroke aphasia, vascular cognitive impairment, and breath-holding spells in children — but **weak and inconsistent signal in cognitively-intact healthy adults**, the population that matters for Dylan. Newer racetams (pramiracetam ~10-30× more potent by weight, oxiracetam cleaner stim flavor, phenylpiracetam DA-flavored stim profile, aniracetam mood/creativity flavor) cover specific subjective use-cases more efficiently. Piracetam at 1.6-4.8 g/day is essentially the "baseline" racetam — the one that proves the family works clinically but doesn't dominate any specific Dylan-relevant niche. **OPTIONAL-ADD** rather than SKIP-FOR-NOW because it's the cheapest, most-evidence-rich, longest-safety-track-record racetam, and a sensible first-touch for someone wanting to know whether the racetam class produces any noticeable effect for them at all (cleanest mechanistic baseline before paying premium for derivatives). Verdict would upgrade to STRONG-CANDIDATE only if a modern healthy-adult RCT replicated meaningful cognitive enhancement at clinical doses (which Malykh 2010 and the 2024-class meta-reviews do not show), or if Dylan ever develops vascular/cognitive-aging concerns. Would downgrade to SKIP-FOR-NOW if a head-to-head trial in healthy adults showed pramiracetam or phenylpiracetam clearly dominates on cognitive-output endpoints for the same dose-cost (which the user-corpus already strongly suggests, even without trial-grade data).

For Dylan-archetype, pramiracetam slots as racetam-of-choice for high-cognitive-load PRN days — strongest pharmacology of the classical racetam family, well-documented HACU mechanism, and clean V4 stack fit (citicoline already covers the obligate choline cofactor). Confidence is MEDIUM not HIGH because (a) the strongest human RCT (McLean 1991, n=4 → expanded; 18-month TBI/anoxia trial) is small and old, (b) Italian Pramistar dementia evidence is open-label / Menarini-funded, (c) cognitive-enhancement evidence in *healthy* adults is modest/anecdotal, (d) Menarini withdrew Pramistar from Italian market 2020 (commercial, not safety, but ends the pharmaceutical-grade source). Would upgrade to STRONG-CANDIDATE if Dylan runs a clean 4-week PRN trial with measurable benefit on cognitive-output days.

For Dylan-archetype, propranolol is a near-ideal PRN tool for sales calls, public speaking, sparring nerves, and pitch-style high-stakes events — A-tier evidence for performance anxiety, no sedation, no cognitive blunting, ~$10-20/mo Rx, and stack-clean with V4. The verdict is OPTIONAL-ADD (not PRIMARY-PICK) only because Dylan's actual performance-anxiety load is unclear and many days don't need it; verdict would upgrade to STRONG-CANDIDATE PRN if he confirms 2-4× per week pitch/sales-call use, or downgrade to SKIP-FOR-NOW if a 4-week trial shows no perceptible delta vs L-theanine + breath protocol on similar events. AVOID for endurance/aerobic training days regardless.

Real adaptogenic and hepatoprotective evidence (well-established in Russian/Chinese pharmacopeia; Pittler 2003 review; Panossian 2008 mechanism), but most data is on non-Western trial populations and the CYP3A4 induction effect is a real stack-conflict risk for anyone on prescription medications. For Dylan (no Rx; cognitive endurance + liver support angle), low-priority OPTIONAL-ADD. Verdict would upgrade to STRONG-CANDIDATE for hepatoprotective indication if ALT/AST elevated on June bloodwork; SKIP-FOR-NOW if any Rx with CYP3A4 substrate enters Dylan's regimen.

Mechanism is unusually well-characterized for a longevity supplement (autophagy is the cleanest aging axis we know) and rodent + human-epidemiology data is consistent. Human RCT base is still thin — the largest cognitive trial (SmartAge 2022, n=100) showed only a non-significant signal. Cheap, exceptionally safe, daily-compatible. Would upgrade to STRONG-CANDIDATE if a positive larger RCT lands or if Dylan's longevity priority moves up; would stay OPTIONAL for a 20yo brain-priority profile.

For 50+ longevity, this is a STRONG-CANDIDATE — best-in-class evidence for restoring aged mitochondrial function (Siegel/Marcinek human ATPmax data, Mitchell 2025 Aging Cell, Rabinovitch healthspan mouse studies). For Dylan-archetype 20yo, mitochondrial decline isn't yet a real driver — anecdotal "energy" effects at peptide-vendor doses (5 mg) are subtle to absent in healthy young adults; clinical doses (40 mg/d) are cost-prohibitive ($150–300/50 mg vial = ~6 days at clinical dose). Would upgrade to STRONG-CANDIDATE if (a) bloodwork shows mitochondrial-dysfunction biomarkers (lactate elevation, low VO2max-for-training-load, persistent post-spar fatigue), (b) Phase 3 ReNEW reads positive in 2026 expanding the human evidence base, or (c) Dylan moves into a longevity-protocol Phase 1 ("rebuild") cycle in his 30s+.

Real but transient PRN tool for low-energy days — clean motivation/drive lift in first 1-2 weeks then tolerance crashes the effect via D1 downregulation; cheap and low-risk so worth keeping in the PRN drawer for 2-3×/week max use, but tolerance permanently rules out daily slot. Stronger candidate for chronic asthenia / post-viral fatigue / MS fatigue archetypes than for a 20yo athlete with already-good baseline energy.

FDA-approved with 20+ years of safety data and a long half-life that makes daily 2.5-5mg cleanly steady-state; cognitive/dementia signal is real but observational-only and not enough to push it past OPTIONAL-ADD for a healthy 20yo. Verdict would upgrade to STRONG with cleaner cognitive RCTs OR a personal interest in the vascular/erectile/CV upside. Would downgrade only on intolerance (headache, back pain) or rare ophthalmologic event.

Plausible mast-cell-driven neuroinflammation thesis (relevant to MMA subconcussive impact context) and a genuine PK improvement over plain luteolin, but the entire human evidence base is preliminary and largely from one investigator group (Theoharides). For Dylan as PRN tool around heavy sparring blocks it is conceivable; as a daily core item it is not justified yet.

Massive replicated literature for acne and photoaging (gold-standard topical retinoid since 1971); but tretinoin is a documented trigger and aggravator of perioral/periorificial dermatitis — Dylan's primary current skin complaint. The right move is "zero-therapy" (stop topicals, eliminate triggers, possibly tetracycline-class oral antibiotic) for the POD first; add tretinoin later once skin is stable, if acne/aging-prevention is a goal. Verdict would upgrade to OPTIONAL-ADD or STRONG-CANDIDATE the moment POD is resolved and Dylan wants to start a long-horizon photoaging-prevention layer.

Decades of clinical and mechanistic data; dose-response and bioavailability differences between ubiquinone and ubiquinol well characterized; benefit is age-stratified — endogenous synthesis declines after ~30 and supplementation rationale is strongest in older adults, statin users, and patients with mitochondrial-disease, CHF, or specific neurodegenerative conditions. **For Dylan (20yo, no statin, no mitochondrial disease, no cardiac pathology, healthy endogenous synthesis): supplementation is plausible-positive but low-impact;** the same mitochondrial-protection real estate is more efficiently covered by ALCAR, astaxanthin, NAC, and (if added) idebenone (which actually crosses the BBB). Verdict would upgrade to STRONG-CANDIDATE if (a) Dylan starts a statin, (b) bloodwork reveals abnormal cardiac biomarkers, (c) genetic data shows an NQO1 or COQ-pathway variant impairing endogenous CoQ10 cycling, or (d) he turns 30+ and wants a low-effort age-related mitochondrial maintenance lever. Verdict would downgrade to SKIP-FOR-NOW only if budget pressure forces choices and ALCAR/astaxanthin already on board.

This is the most-evidenced "longevity supplement" available OTC as of May 2026 — three distinct human RCTs (Andreux 2019, Liu 2022, Singh 2022 ATLAS-derived) consistently show measurable improvements in mitochondrial gene expression, plasma C-acylcarnitine biomarkers, and modest muscle endurance gains in older adults at 500–1000 mg/day. **Effect size is real but modest, age-stratified (best signal in 50+), and chronic (4+ months for muscle endpoints).** For Dylan at 20: low-priority because (a) endogenous mitochondrial quality is already near peak, (b) muscle endurance signal in young athletes is unstudied and likely below detection threshold against training-driven adaptation, (c) ~30–40% of Western adults are urolithin "non-producers" — Dylan's producer status is unknown until 23andMe + microbiome testing or direct urinary metabolite assay. Verdict moves to **STRONG-CANDIDATE at 30+** and STRONG-CANDIDATE today *if* microbiome non-producer status confirmed. **What would change verdict:** confirmed urinary non-producer status post-pomegranate-load test → upgrade to STRONG-CANDIDATE now (specific physiological gap to fill); positive young-athlete RCT readout → upgrade.

Cheap baseline insurance for a 20yo athlete with moderate-choline diet — covers B1/B2/B3/B5/B7 gaps not addressed by V4 (V4 already provides B6 indirectly via NAC-supported methylation, B9 via fish-oil-paired methylation context, and B12 indirectly via cobalamin-rich animal protein). The specific case for the *methylated* form depends on Dylan's pending MTHFR genotype (~June 5-15, 2026 23andMe) — if C677T heterozygous or homozygous (~30% and ~10% of population respectively), methylated B-complex is a genuine pharmacogenomic upgrade, not marketing. At ~$25-40/mo for Pure Encapsulations B-Complex Plus or Thorne Basic B, it's the cheapest possible "all your B-vitamin demands probably covered" insurance against subtle cofactor deficiency. Verdict moves to STRONG-CANDIDATE post-23andMe if MTHFR variant confirmed.

For Dylan's specific cubital tunnel / ulnar nerve compression context, the Wolverine Stack is the single most mechanism-aligned non-surgical intervention available — peripheral nerve regeneration is BPC-157's strongest preclinical data set (sciatic crush/transection/spinal cord rat models), and TB-500 supplies the cell-migration arm that BPC-157 alone doesn't fully cover. Verdict is OPTIONAL-ADD (not STRONG-CANDIDATE) because (a) it's a targeted recovery intervention, not a daily stack member, (b) Dylan should run behavioral protocol (night splint, ergonomic pad, sleep position) for 2-4 weeks first since 50%+ of mild cubital tunnel resolves without peptides, (c) the cubital-tunnel-cycle protocol already exists as the Dylan-specific implementation. Confidence is MEDIUM-HIGH because both component evidence bases are individually solid (BPC-157 = >180 Sikiric papers + 2025 Vasireddi systematic review of 36 articles; TB-500 = robust rodent + equine data + RegeneRx human ophthalmic/cardiac trials on full TB-4); the *combination* is supported by one published human study (Lee & Padgett 2021, n=16 knee pain, 87.5% improvement combined or BPC-only) and overwhelming biohacker community consensus. Would upgrade to STRONG-CANDIDATE post-positive Dylan N=1 trial. Would downgrade to WATCH-LIST if independent confirmation of BPC-157 effects fails to materialize OR if cancer-promotion signal emerges in any human cohort.

Mechanistically interesting — NNMT inhibition is a clean adipose/methylation/NAD-axis lever in rodents (Kraus 2014 onward), and the pep-pedia community is enthusiastic (n=1569 responses, 71% "would recommend" yes/probably-yes, 63% "no side effects" reported). **Zero human RCTs.** All published efficacy data is rodent or cell-culture. Sold strictly as research chemical with high vendor-quality variance and no COA standardization across the market. Chronic safety profile entirely unknown. **For Dylan (20yo MMA, brain priority, lean):** primary marketed effect (fat loss) is irrelevant; theoretical NAD/SAM-preservation angle exists but is better served by NMN/NR + methyl support already in play. **WATCH-LIST low priority — revisit only if a credible Phase 1/2 human trial reads out positive.** What would change verdict: any human RCT (positive or negative) at any endpoint; FDA IND filing; reproducible LC-MS purity data across the major vendors.

Polanski lab body of work (2007-2020, multiple replicated rat + cell-culture papers) is genuinely substantial preclinical evidence for a multimodal dopaminergic neurorestorative profile rare in the nootropic literature — TH upregulation, hippocampal dopamine elevation, dendritic outgrowth, BDNF/artemin induction, anti-inflammatory microglial effects, MPP+ neuron rescue. BUT: zero human trials of any kind, dual MAO-A/B inhibition (not the "selective MAO-B" some sources claim — IC50 favors MAO-A 15.5×) raises tyramine + serotonin-syndrome theoretical concerns at chronic dosing, documented UVA-photosensitization with DNA damage in cell models is a real and largely unquantified human risk, vendor identity verification is non-trivial for a research-chem with limited Trustpilot history, and the V5 stack already covers neurogenic + dopaminergic axes (cerebrolysin, bromantane, semax/adamax, low-dose selegiline) with vastly better human safety data. WATCH-LIST not SKIP because the mechanism profile is genuinely interesting and biohacker reports skew positive at 5-15 mg, but the risk/benefit at age 20 with strong V5 alternatives makes "wait for human safety data or independent replication" the correct call. Would upgrade to OPTIONAL-ADD only if (a) a human Phase 1 / observational safety study lands, (b) photosensitivity is quantified at biohacker doses (not just UVA cell-culture), or (c) Dylan develops a specific dopaminergic-deficit indication (post-modafinil tolerance, post-stim tolerance reset).

Mechanism is one of the most interesting in the pipeline (selectively amplifies endogenous BDNF/NGF without forcing constant Trk activation), but only Phase 1 + Phase 1b complete (April 2026), no human efficacy data, no Phase 2 readouts, and the only research-chem suppliers are Everychem (vendor flagged AVOID in Dylan's profile) and Probechem with no community track record. WATCH-LIST not SKIP because Phase 2a is funded (€2.5M EIC grant Feb 2025, first payment Dec 2025) and TBI is a stated indication that maps directly to Dylan's MMA-subconcussive thesis. Would upgrade to OPTIONAL-ADD if: (a) Phase 2a Alzheimer's readout shows cognitive benefit, OR (b) a non-Everychem vendor with COA-verified material emerges and someone else trials first.

Plausibly a longer-acting Selank for anxiolytic use, but evidence base is essentially zero direct studies — all "Adalank does X" claims are really "Selank does X, and we assume Adalank does too because the active sequence is identical, just chemically armored." For Dylan, regular Selank already covers PRN anxiolysis with a real Russian Rx supply chain (CosmicNootropic) and verifiable product. Adalank earns a WATCH-LIST slot rather than SKIP because the chemistry rationale is sound (dual end-cap protection is the same logic that makes NASA worthwhile vs Semax) and a verified COA + 4-week trial replicating Selank effects at lower mcg with longer duration would justify upgrade. Promote to OPTIONAL-ADD if (a) verified vendor + COA, (b) Dylan's Selank PRN trial shows benefit but duration limitation matters, or (c) independent published PK confirms the longer half-life claim.

Mechanism is genuinely novel and well-aligned with Dylan's late-chronotype migration + sleep-without-next-day-sedation profile, and on paper it's the closest thing to a "phase-advance + mood-bright + anxiolytic" combo Rx that exists. But the evidence base is poisoned by publication bias (Servier sponsored almost every trial, unpublished trials trend negative), the rare-but-real hepatotoxicity signal requires LFT monitoring at 3/6/12/24 weeks, and US access requires gray-market import from Indian pharmacies. Would shift to STRONG-CANDIDATE only if (a) Dylan's behavioral chronotype migration plateaus before reaching midnight bedtime, (b) bloodwork shows clean baseline LFTs, and (c) a competent EU/Australian telehealth prescriber can run the LFT monitoring schedule. Otherwise melatonin 0.3-0.5 mg + tryptophan does ~80% of the same job for $5/month with no liver risk.

AHK-Cu has a clean ex vivo + small Korean cosmetic-RCT mechanism story for hair follicle elongation, but A-tier human RCT evidence is thin and most efficacy data is from formulations co-bundled with minoxidil/biotin/biochanin-A (Capixyl etc.) — the marginal contribution of AHK-Cu alone is hard to isolate. For Dylan at 20 with a full hairline and no MPB family-history flag in profile, AHK-Cu is a solution-in-search-of-a-problem. WATCH-LIST entry: revisit if (a) hairline starts receding, (b) Dylan stacks minoxidil for any reason, (c) future bald-protocol planning. For skin/wound use, GHK-Cu is strictly better-evidenced and cheaper to find.

Real mechanism + concrete Dylan-relevance (cubital tunnel = peripheral small-fiber neuropathy; ARA-290's published human data is in sarcoidosis-associated small-fiber neuropathy, mechanistically the most adjacent indication). Animal data for sciatic nerve crush + axotomy is robust. **The case for adding ARA-290 to Dylan's BPC-157 + TB-500 cubital-tunnel protocol is mechanistically credible but evidentially thin** — only one published RCT (Heij et al. 2012, n=22, modest pain reduction in sarcoidosis-SFN), small follow-up cohorts, no peripheral-nerve-compression human trial. The verdict is WATCH-LIST not OPTIONAL-ADD because (a) the BPC-157 + TB-500 stack already covers the same nerve-regeneration territory with better-replicated rodent data + larger biohacker community evidence base, (b) ARA-290 sourcing through peptide vendors is more variable than BPC-157/TB-500 (smaller market = higher per-vial cost + lower COA standardization), (c) the marginal benefit of adding a third peptide to the cubital-tunnel cycle is unclear, and (d) the EPO-derived class membership creates a non-zero residual concern about off-target erythropoietic signaling at high doses or with long use, despite the molecular case for IRR-only activity. Confidence MEDIUM not LOW because the small-fiber-neuropathy targeting is genuinely mechanism-aligned for cubital tunnel (which has both demyelinating and small-fiber components when chronic), and the EPO-without-erythropoiesis safety thesis has held in 15+ years of trial work without a thrombotic / hematocrit / blood-pressure signal. Would upgrade to OPTIONAL-ADD if (a) Dylan's first 8-week BPC-157 + TB-500 cycle produces only partial cubital-tunnel response and a second cycle adding ARA-290 is reasonable, (b) a peripheral-neuropathy or post-surgical-nerve RCT replicates the sarcoidosis-SFN signal, or (c) Araim Pharma advances cibinetide to a confirmatory Phase 3 with positive readout. Would downgrade to SKIP-FOR-NOW if any erythropoietic signal emerges in long-term cohorts or a thrombotic event surfaces in self-experimenter community reports.

Mechanistically the cleanest selegiline successor on paper (pure CAE without MAO inhibition, ~130× more potent in rat models, broader serotonergic coverage) and Knoll's animal lifespan + tumor-suppression data is impressive — but ZERO published human RCTs, only one Phase 2 Parkinson's program by Fujimoto Pharma (status pending/unclear, no public results), and sub-mg dosing demands research-chem identity + COA confidence at a level where dose-error catastrophe is real. Verdict would upgrade to OPTIONAL-ADD with HIGH confidence if a single well-designed human Phase 1 PK/safety study landed; would downgrade to SKIP-FOR-NOW if a credible hepatotoxicity or arrhythmia signal emerges (the benzofuran scaffold has class-level liver concern flagged for benzbromarone/benzarone — not yet shown for BPAP).

Mechanistically elegant (avoids the PDE4D emetic site that doomed rolipram), preclinical evidence is A-tier for memory/LTP, and the 2021 Phase 2 Fragile X trial (Berry-Kravis, Nature Medicine) hit secondary cognition/language endpoints — but PICASSO Alzheimer's failed primary in 2020, EXPERIENCE Phase 2b/3 Fragile X readouts (post-Oct 2025) are still pending, and there are zero healthy-young-adult cognitive enhancement RCTs. For Dylan-archetype: insufficient evidence to commit; revisit after EXPERIENCE readout. Confidence would jump to MEDIUM if EXPERIENCE-301/204 hit primary endpoints, and to HIGH only if a healthy-adult cognitive-enhancement RCT replicates the 10-20mg One Card Back signal from the 2017 Phase 1.

Tripeptide with at least a published sequence (Ala-Glu-Asp) and a plausible biological hook into type XI collagen biology — slightly above the average Khavinson black-box peptide. But Western-indexed RCTs are zero, evidence is Russian-only, and for Dylan's joint use case (MMA load, cubital tunnel) BPC-157 + TB-500 dominate on evidence and felt effect. Watch-list rather than skip because the cartilage angle is real for an aging OA cohort, and Dylan may want it on the radar later.

For Dylan-archetype, clonidine is **directionally wrong as a daily compound** (heavily sedating, BP-lowering, anti-alertness — same vector mismatch as guanfacine but worse) but has a **narrow PRN role** for stim-rebound mitigation if afternoon Adderall/modafinil crashes ever become a problem, sleep-onset rescue (0.05-0.1 mg HS), or pre-sales-call somatic anxiety where propranolol is contraindicated (asthma) or insufficient. The verdict is WATCH-LIST rather than SKIP because the PRN sleep-onset and stim-rebound use cases are real and well-documented, but **propranolol covers performance anxiety better with no sedation, and daridorexant/tryptophan/apigenin cover sleep onset better with cleaner pharmacology**. **Rebound hypertension on abrupt cessation is a real risk** that means even PRN use must be cadence-aware. Verdict would change to OPTIONAL-ADD PRN only if a specific use case emerges that the existing V4/V5 stack doesn't cover (e.g., Dylan goes on amphetamine for ADHD and needs afternoon-crash mitigation, or PTSD nightmares emerge as a target).

For Dylan-archetype, cGP is mechanistically interesting — a homeostatic IGF-1 modulator that **normalizes** rather than amplifies free IGF-1, with a clean side-effect profile in human trials and neuroprotective signal in stroke/MCI populations. **But cGP is the same molecule as cycloprolylglycine (cPG), the active metabolite of noopept** — already documented as Dylan's noopept entry, which means direct cGP supplementation is functionally redundant with the noopept watch-list compound. Direct cGP via NZ blackcurrant or pure synthetic offers a non-prodrug delivery path (avoiding noopept's parent molecule + first-pass hydrolysis) and is more food-grade-positioned, but the active signaling species is identical. Confidence is MEDIUM not HIGH because (a) human clinical trial data is limited to a small number of NZ-based studies in MCI + post-stroke, (b) the IGF-1 homeostasis mechanism is well-characterized in animal models but mostly inferred in humans, (c) NZ blackcurrant cGP content is variable across products and dose-equivalence to noopept is rough. Verdict would upgrade to OPTIONAL-ADD if (i) Dylan wanted a food-grade non-Russian-peptide route to the same cPG signaling territory, (ii) post-concussion or stroke recovery context emerged, or (iii) bloodwork suggested IGF-1 dysregulation that a homeostatic modulator could address. Verdict would stay WATCH-LIST otherwise — cGP is on the radar as an interesting endogenous-metabolite candidate but does not displace noopept's slot in the cognitive-enhancement comparison set.

Best-in-class DORA for next-day cognition (8-hour half-life vs 12 hr suvorexant / 17-19 hr lemborexant), strongest total-sleep-time effect at 50 mg in head-to-head NMA, sleep-architecture preserving, low abuse liability. But Dylan does not have insomnia — he has a chronotype problem, which DORAs do not directly fix. Reserved as the *escalation* tool if 4-6 weeks of behavioral chronotherapy + l-tryptophan + magnesium fail to migrate his bedtime. Verdict would shift to STRONG-CANDIDATE only if (a) sleep onset stays >45 min after non-pharmacological stack, (b) WASO becomes a real complaint, or (c) a sleep architecture concern surfaces in actigraphy.

Mechanistically novel hexapeptide with a famous in-vitro potency claim, but the path to humans is broken: ZERO completed human trials of DIHEXA itself; the prodrug fosgonimeton ran for >7 years and failed the Phase 2/3 LIFT-AD primary endpoint in 2024; Athira's CEO Leen Kawas was found to have manipulated images in the foundational dissertation and four supporting Harding-lab papers (2021 internal investigation, Jan 2025 DOJ $4M False Claims settlement); the HGF/c-Met pathway is an oncogenic driver targeted by FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) which makes a chronic agonist of the same axis a non-trivial theoretical concern; vendor identity verification is uniquely fraught for a hexapeptide that is cheap to substitute. For Dylan-archetype (20yo, brain priority, no cognitive deficit, MMA recovery context with theoretical wound-healing/proliferation risk) the upside is poorly defined and the risk profile is wrong. Would upgrade to OPTIONAL-ADD only if (a) an independent academic lab — not Harding/Wright/Kawas-adjacent — replicates the synaptogenesis result with clean blinded methodology, (b) some honest human pharmacokinetic study lands (any route), or (c) a credibly post-fraud follow-on AD or PD trial reads out positive on a clean cognitive endpoint.

Interesting peptide with mechanism-plausible sleep + stress + endocrine effects, but the human evidence base is dominated by 1980s-90s small-N Russian/European trials with essentially zero modern Western RCT replication. For Dylan specifically: late chronotype is a phase-shift problem (DSWPD), not a sleep-onset or sleep-architecture problem — DSIP's claimed slow-wave sleep enhancement does not address circadian phase, which is what melatonin + light protocol is targeting. WATCH-LIST because pep-pedia coverage warrants documentation, but no near-term action item. Verdict would shift to OPTIONAL-ADD only if (a) Dylan's chronic pain or stress phenotype changes, (b) a credible modern RCT lands, or (c) post-V5 sleep architecture data (Colmi R06 or formal PSG) shows N3 deficiency that warrants targeted intervention.

Mechanistically interesting and remarkably clean safety profile across decades of Russian use, BUT: (a) ~all pivotal evidence is single-lab (Khavinson/Anisimov, St. Petersburg Institute of Bioregulation and Gerontology) with 196 group-held patents, commercial sales conflict, and no NIA-ITP-grade replication; (b) the use-case for a 20yo with already-near-peak telomere length is theoretically weak — telomere attrition is plateaued in young adulthood, the Russian cohort data is in 60-80yo subjects; (c) the "receptor priming for downstream peptides" rationale Dylan flagged is a vendor/community claim, not directly proven; (d) Western academic uptake remains near-zero. **Would upgrade to OPTIONAL-ADD if:** an independent Western lab publishes telomerase activation replication in primary human cells (one such 2025 paper exists — see Evidence section, but author affiliation needs vetting); or if Dylan's Phase 3 (post-30) longevity protocol moves into actual implementation. **For now: park on watch-list; revisit at age 25-30 or when independent replication firms up.**

A-tier mouse evidence for selective senolysis (Baar 2017 Cell + multiple 2024-2025 follow-ups), ZERO human trials, biohacker-tier anecdote only. At 20yo with minimal senescent cell burden, intervention is theoretical and the risk/reward is wrong direction. Would upgrade to OPTIONAL-ADD if (a) human Phase I safety drops, (b) Dylan reaches 35-40+, or (c) post-injury senescent burden becomes plausible (chronic inflammation, persistent tissue damage).

Strong A-tier evidence in mild-moderate AD (Cochrane meta confirms cognitive + ADL benefit; comparable efficacy to donepezil); the dual mechanism (AChEI + α7 nAChR allosteric potentiation) is genuinely interesting for working memory and is what lucid-dreaming community exploits with WBTB. **For a 20yo healthy MMA athlete already running citicoline as chronic choline donor: not a daily-stack candidate** — desensitization at α7 nAChR is real (so chronic daily use blunts the unique mechanism), cholinergic side effect load (N/V, sleep disruption, weight loss) is meaningfully higher than huperzine, and the AD benefit doesn't extrapolate to healthy young brains where ACh tone is already adequate. **Worth keeping on the list as a 1-2× per month lucid-dreaming PRN tool (4-8 mg, WBTB protocol)** — that's the only Dylan-relevant use case that the dual mechanism actually delivers on. Verdict would shift to OPTIONAL-ADD if (a) emerging α7 nAChR data in healthy adults firmed up working-memory effect, or (b) Dylan's 23andMe shows APOE ε4+ (cholinergic deficit appears earlier).

This file is the master / umbrella entry covering glutathione as a substance across all routes (oral free, liposomal, sublingual, s-acetyl, intranasal, IV, IM, inhaled). Route-specific verdicts and pricing live in companion files (`liposomal-glutathione.md`, `s-acetyl-glutathione.md`). For Dylan specifically: WATCH-LIST. NAC 1200 mg/day in V4 already supplies the rate-limiting cysteine substrate for endogenous GSH synthesis, crosses the BBB efficiently, and has the larger evidence base — direct GSH supplementation is largely redundant in a healthy 20yo with intact GCL capacity. The forms with the strongest evidence (IV for liver disease, intranasal for Parkinson's adjunct) are not Dylan-relevant. Verdict-confidence is MEDIUM-HIGH because the route-dependence is real (IV and intranasal genuinely deliver where oral can't) but the use case for Dylan is weak. Verdict would upgrade to OPTIONAL-ADD if (a) chronic NAC bloodwork shows persistent oxidative stress (low GSH/GSSG ratio, elevated 8-OHdG / F2-isoprostanes / MDA), (b) a GSH-synthesis-capacity genetic deficit emerges (GCLC/GCLM low-function variants, GSTM1/T1 null), or (c) Dylan develops a route-specific indication (post-impact intranasal protocol, hepatic stress requiring IV).

Mechanistically interesting endogenous mitochondrial peptide with the longest historical trail of any MDP (discovered 2001, 24+ years of preclinical work) and convergent positive signals across Alzheimer's, ischemia, atherosclerosis, type 2 diabetes, and aging models — but **zero published human RCTs of native Humanin or any analog as of May 2026**. All efficacy evidence sits in cell and rodent work; no analog has reached even Phase 1 in registered trials. The peptide-vendor scene around Humanin is small and quality is questionable. **For Dylan: NOT-ACTIONABLE-YET.** Brain-priority justifies tracking the literature given the Aβ-neuroprotection mechanism, but at 20 with no neurodegenerative target, no human dosing established, and higher-yield V4/V5 brain levers already deployed (Cerebrolysin, citicoline, DHA, modafinil, bromantane, Adamax/Semax), Humanin is a watch-the-pipeline compound, not an experiment-now compound. Would upgrade to OPTIONAL-ADD if (a) any registered Phase 1 opens with safety + biomarker readout, or (b) Cohen lab / independent group publishes a human pharmacokinetic study establishing dosing.

Real signal in MCI/AD (Craft 2012) and healthy adults (Benedict 2004/2007) — but SNIFF 2020 missed primary endpoint largely due to a documented delivery-device failure mid-trial (the ViaNase II device performed differently than the original ViaNase I), confounding interpretation. Mechanism is well-characterized and side-effect profile is exceptionally clean for a chronic CNS-active intervention. For Dylan: not actionable until (a) 23andMe APOE status is in (APOE4 carriers show stronger cognitive response signals), (b) a cleaner delivery path exists than off-label compounded insulin + research-grade atomizer, (c) some direct healthy-young evidence beyond the small Benedict cohorts. Verdict would upgrade to OPTIONAL-ADD if APOE4 + Kurve VP3 or comparable device becomes accessible. Verdict would downgrade to SKIP-FOR-NOW if SNIFF-2 fails replication in 2027.

For Dylan specifically, ISRIB is a mechanism-aligned candidate for subconcussive-impact memory protection (preclinical TBI data is striking and replicated), but A-tier evidence is animal-only, the only human pharma development path (Calico/AbbVie fosigotifator analog) failed in 2025 ALS Phase 2/3 and the partnership ended November 2025, research-chem identity/purity carries vendor risk, and chronic dosing has a real (not theoretical-only) ubiquitin-proteasome-system concern published 2024. Would upgrade to STRONG-CANDIDATE if (a) Dylan takes a documented concussion and wants an aggressive recovery stack, or (b) a CNS-penetrant successor (DNL343 / next-gen eIF2B activator) gets cleaner human safety data, or (c) Cerebrolysin + V4/V5 baseline is locked and he wants one experimental brain-protection layer on top with informed-consent risk acceptance.

For Dylan-archetype (20yo, brain-priority, MMA, NO current depression), ketamine is a hold-for-trigger compound — not daily, not prophylactic, not for cognitive enhancement. The TRD evidence is A-tier and the rapid-antidepressant mechanism is genuine (Berman 2000 → Krystal/Sanacora replications → Spravato approval 2019), but Dylan has no depression and no acute TBI requiring ICU sedation. The TBI-protection angle is theoretically attractive (NMDA glutamate excitotoxicity is a major secondary-injury mechanism in concussion) but the human data is mixed-to-neutral, the clinical trials are in severe TBI/ICU settings, and the protective effect requires acute administration immediately post-injury — not a chronic biohacker tool. Chronic recreational/at-home use carries real risks: ketamine bladder (interstitial cystitis, often irreversible), cognitive blunting in heavy users, fast tolerance, and dependence potential despite earlier "non-addictive" framing. Verdict would upgrade to OPTIONAL-ADD-PRN if Dylan develops treatment-resistant depression that fails standard SSRIs/SNRIs/bupropion (then KAP via licensed clinic, 6-session induction, monthly maintenance). Verdict would upgrade to STRONG-CANDIDATE for a different archetype (current TRD patient who has failed two antidepressants). Verdict would drop to SKIP-PERMANENT if Dylan demonstrated any compulsive substance use pattern, history of dissociative misuse, or urinary symptoms.

For Dylan specifically — KLOW is a multi-component stack where the GLOW subset (GHK-Cu + BPC-157 + TB-500) already overlaps directly with the planned cubital tunnel cycle, and KPV may add value if perioral dermatitis persists despite clotrimazole + behavioral fixes. The full KLOW (with LL-37) is not load-bearing for Dylan's current targets — LL-37 is the wildcard with the thinnest evidence base, the hardest sourcing, and the only component with cytotoxicity-at-high-concentration concerns. WATCH-LIST means: keep the 3-peptide GLOW subset on the active shortlist for the cubital tunnel + skin protocol (already documented in stacks/cubital-tunnel-cycle.md and stacks/klow-glow-stack.md), but do not run the full 5-peptide KLOW unless skin/gut symptoms escalate to a degree that justifies the LL-37 sourcing/cost overhead. Confidence is MEDIUM because (a) zero clinical trials exist on this specific blend, (b) each component has its own evidence-base limitations (single-lab dominance for BPC-157, sparse human data for KPV/LL-37, gray-market sourcing variability across all 5), and (c) the synergy claim is mechanism-plausible but not RCT-validated. Would upgrade to OPTIONAL-ADD if (a) Dylan's perioral dermatitis or gut symptoms escalate AND clotrimazole/behavioral fixes fail, (b) the cubital tunnel cycle plateaus on BPC-157 + TB-500 alone and adding GHK-Cu + KPV produces incremental gain. Would downgrade to SKIP-FOR-NOW if behavioral measures resolve cubital tunnel + skin issues without peptide intervention.

Mechanism is genuinely novel (true inverse agonist + insurmountable antagonist with 100x istradefylline affinity), Phase 2b adjunct-to-levodopa primary endpoint hit cleanly with favorable safety, AND the original task-brief assumption "not commercially available" is wrong — Umbrella Labs and others sell it as research chem with COA. But Kyowa Kirin discontinued the program in July 2022 (regulatory/timeline calculus, not efficacy), no Phase 3 data exists or will exist, healthy-adult cognitive-enhancement evidence is zero (extrapolated entirely from istradefylline data which itself is mostly null on cold cognition), and Dylan has zero use case beyond curiosity. Verdict shifts to OPTIONAL-ADD only if (a) replicated nootropic anecdote base develops with consistent positive cognitive signal, AND (b) Dylan's modafinil + bromantane V5 stack underdelivers on motivational-drive vector. Verdict shifts to SKIP-PERMANENT if research-chem batches show purity/safety problems or if any A2A-class neuropsychiatric signal (impulse-control, hallucinations) emerges in non-PD users.

Cleaner side-effect profile than MTII (no priapism, much less nausea, no chronic appetite suppression) is the genuine pharmacological advance, and Dylan's Nordic-ancestry + minimal-sun-exposure phenotype is the textbook user case where MTI's photoprotection rationale is plausible — but the long-term safety question (does stimulating melanogenesis in DNA-damaged or pre-malignant melanocytes increase melanoma risk?) is unresolved at peptide-community doses, the FDA approval is for a narrow orphan indication (EPP) that doesn't map onto cosmetic use, and the gray-market injectable form is structurally distinct from the Scenesse implant (uncontrolled bolus pharmacokinetics vs. 60-day controlled release). For a brain-and-MMA-priority 20yo, this sits in WATCH-LIST: real mechanism, plausible fit, but evidence-of-safety bar isn't met. Verdict shifts to OPTIONAL-ADD if (a) 23andMe shows responsive MC1R genotype, (b) Dylan establishes dermatology baseline + total-body photography, and (c) he commits to 3-6 month derm follow-up. Verdict shifts to SKIP if 23andMe shows two LOF MC1R variants (mechanistically dead) OR if family history reveals melanoma / FAMMM.

The mechanism is real and well-characterized — Russel Reiter's life work plus replicated oncology and ICU/sepsis adjunct trials establish high-dose melatonin as a legitimate antioxidant + mitochondrial protectant. For Dylan's specific concern (subconcussive impact load from MMA), the rodent TBI literature is robust and the human-translation evidence is plausibility-tier rather than proven. Verdict is WATCH-LIST rather than STRONG-CANDIDATE because (1) chronic high-dose use in healthy 20-year-old males is essentially unstudied — the pharmacological literature is in cancer patients, ICU patients, and elderly populations where the risk/reward calculus is different; (2) heavy sedation, vivid dreams, and morning grogginess are essentially universal at 20-50+ mg, which conflicts with Dylan's brain-priority value system; (3) HPG-axis caveats — while clinical evidence in young males at supplement doses is reassuring, the data at 50-300 mg chronic dosing is genuinely thin. **The intermittent post-sparring PRN protocol (20-50 mg HS the night of a hard sparring session, ≤2× per week)** is the rational way to capture mechanism-aligned neuroprotection benefit with minimal chronic exposure. Verdict shifts to OPTIONAL-ADD if a credible TBI / subconcussive-impact human RCT lands positive; shifts toward STRONG-CANDIDATE only in a specific recovery context (post-major-illness, post-significant-head-injury). For chronic daily high-dose, verdict stays WATCH-LIST indefinitely absent better human longitudinal safety data in young adults.

Strong longevity rationale in older / pre-diabetic adults (Barzilai TAME thesis), but for a 20yo metabolically healthy MMA athlete the case is weak: blunts exercise-induced mitochondrial biogenesis (Konopka 2019), no glycemic problem to fix, and B12 depletion is real on chronic use. Good compound, wrong stage of life. Reconsider after age 35-40 or if a future bloodwork shows insulin resistance.

Mechanistically the form of NAC that *should* work for brain protection — ~7-30× higher BBB penetration than parent NAC, demonstrably raises brain (not just liver) GSH in animals, theoretical fit-for-purpose for combat-sport subconcussive impact protection. But: (a) no healthy-adult RCTs anywhere — entire human evidence base is case reports + small open-label series in HIV cognition + addiction; (b) decades-shorter safety record than parent NAC; (c) sourcing is gray-market with limited reliable US vendors. WATCH-LIST until either a credible RCT lands, a reputable vendor with third-party COA emerges, or a compelling personal reason exists to swap V4 NAC. Verdict would upgrade to OPTIONAL-ADD if a reliable supplier with batch-verified purity becomes available; would upgrade to STRONG-CANDIDATE if any RCT in healthy adults or athletes confirms the brain-GSH benefit predicted by animal data.

Real cognitive effect (Heishman 2010 meta is A-tier — fine motor, alerting attention, episodic memory in non-smokers, small-medium ES) but **adolescent dependence risk is uniquely high for Dylan at 20 with developing prefrontal cortex**. The compound itself is well-characterized; the verdict is conservative because the cost (dependence + adolescent neurodevelopment cost) is real and irreversible while the benefit (gum 2-4 mg PRN) is replicable by other PRN tools (caffeine + theanine, modafinil, tyrosine) without the dependence load. Verdict would shift to OPTIONAL-ADD only after age 25+ with strict PRN-only protocol verified across 6+ months.

For Dylan's MMA subconcussive prophylaxis use case, mechanism is genuinely interesting — L-type Ca²⁺ flux is one of the canonical mechanisms of impact-induced neuronal injury, and nimodipine is the most BBB-selective CCB available — but human evidence in healthy young athletes is essentially zero, the FDA-approved indication (aneurysmal SAH vasospasm) is mechanistically downstream of the same Ca²⁺ pathology in a totally different population, and the head-injury RCTs (HIT-I through HIT-IV) were disappointing despite the clean mechanism. Verdict would upgrade to OPTIONAL-ADD if (a) any positive human RCT in mild TBI / subconcussive impact reads out, (b) sourcing solidifies (US Rx is cheap but supply-disrupted; Indian OTC works but adds friction), or (c) Dylan develops a documented concussion (then nimodipine becomes part of acute post-injury Ca²⁺-buffering protocol alongside cerebrolysin / NBP). For now: real interest signal but premature for V5 inclusion; reassess at V6 review.

For Dylan-archetype, noopept is a credible nootropic with a genuinely interesting mechanism (endogenous-cPG generation, BDNF upregulation, AMPA potentiation) and a strong Russian clinical signal in cognitive impairment populations. But Dylan is already running a Russian-peptide-heavy V5 stack (Semax, Bromantane, Adamax, Selank PRN) that covers the same neurotrophic + cognitive + anxiolytic territory through better-evidenced routes. Noopept's marginal contribution on top of that stack is unclear. Confidence is MEDIUM not HIGH because (a) virtually all human efficacy data is single-source Russian (Ostrovskaya / Zakusov Institute lineage), (b) Western replication is essentially absent, (c) BDNF claims rest on Ostrovskaya animal data with thin healthy-adult human BDNF measurement, (d) the "1000× piracetam" framing is widely misunderstood. Verdict would upgrade to OPTIONAL-ADD if (i) Adamax or Semax fails to deliver subjective benefit and a different-mechanism Russian compound is wanted, or (ii) Dylan wants a sublingual fast-onset option for high-cognitive-demand acute use. Verdict would upgrade to STRONG-CANDIDATE only with independent Western RCT.

Hippocampal neurogenesis is theoretically high-value for Dylan's brain-priority + MMA subconcussive thesis, and the compound has unusually long human safety exposure (~3 trials, no serious AEs). But TWO independent Phase 2b failures on the primary MADRS endpoint (Neuralstem 2017, Alto 2024) — the second specifically designed to rescue the responder signal via a verbal-memory cognitive biomarker — substantially weaken the "actually does something useful in humans" thesis. Animal hippocampal volume gains did not translate to MRI volume changes in human Phase 1b. Until Alto's Phase 3 (or a re-purposing readout in PTSD/bipolar) reads positive, this is a "wait, don't pay" not a "buy". Would upgrade to OPTIONAL-ADD if (a) Alto Phase 3 hits, (b) credible long-term human neurogenesis biomarker data emerges, or (c) Dylan develops a specific hippocampal-deficit indication (post-concussion verbal memory drop).

Identical compound to noopept.md — verdict, mechanism, dosing, sourcing, and full analysis live there. This file exists for searchability under the INN name "omberacetam" used by some Western and pep-pedia-style sources.

Robust preclinical (rodent AD/TBI/aging) data on neurogenesis + cognitive rescue, plus mechanistic appeal to Dylan's brain-priority thesis (BDNF axis, anti-amyloid, hippocampal). However: human evidence is essentially absent (Phase 1 safety only), gray-market sourcing is variable, and Cerebrolysin already covers the same neurotrophic-mimetic space with decades of human RCT data. Would upgrade to OPTIONAL-ADD if (a) Phase 2 human data reads out positive, (b) reliable QC'd vendor channel emerges, (c) Dylan accumulates subjective signal that Cerebrolysin alone leaves gaps in.

Mechanism is genuinely novel and well-characterized at the preclinical level — TREK-1 blockade is the most robustly validated rapid-antidepressant target outside of ketamine/NMDA, and the Mazella lab's mouse data is internally consistent across forced swim, tail suspension, and chronic social defeat models. **But there are zero published human trials of PE-22-28 (or any spadin analog) as of May 2026.** No human PK, no human dosing, no human safety, no human efficacy, no human anything. For Dylan — 20yo, no diagnosed depression, brain-priority profile — there is no use case that justifies experimental peptide self-administration when the mechanism only matters in clinical depression, the Mazella data has not been independently replicated outside the originating lab, and far better-evidenced mood tools (selank for anxiety, agomelatine for circadian-mood combo, bupropion if anhedonia ever emerges) cover any plausible Dylan-relevant indication with orders of magnitude more safety data. Verdict would shift only on (a) at least one peer-reviewed Phase 1 human PK/safety study, (b) Dylan developing treatment-resistant depression (extremely unlikely given current presentation), or (c) independent replication of Mazella mouse data by a non-Nice group. Until then: watch the literature, do not order.

Re-evaluated from prior SKIP-FOR-NOW after user surfaced an external longevity-protocol claim of "Phase 3 receptor priming." Honest assessment: mechanism class is interesting (epigenetic / DNA-binding tripeptide), some legitimate in vitro neuroprotection signal (oxidative stress, dendritic spine preservation in 5xFAD-M mouse model), one small Russian human TBI/cerebrasthenia trial (n=72, oral 0.4 mg/d × 20-30 d). But ALL evidence still originates from Khavinson's group, no independent Western replication, no ClinicalTrials.gov registry entries, and the "receptor-priming" / "Phase 3 prime" claim from external longevity protocols is an inferential leap from in vitro signaling work — it has not been demonstrated clinically. Move to OPTIONAL-ADD only if (a) Dylan is already running an Epithalon longevity cycle, (b) bloodwork is clean, (c) cost is trivial relative to other priorities. Otherwise Cerebrolysin + Semax + Adamax already cover the brain-protective peptide role with multi-source evidence.

One small Hansl-and-Mead 1978 trial (n=47, single 5 mg dose, double-blind crossover) reported dramatic 24h verbal-recall improvement (132-143% of baseline overall; 187-191% in bottom-60% memorizers; 200-205% at 1 week in that subgroup) — and in 47 years that finding has never been replicated. Patent-holder ran the only trial. Inventor died, patent expired, legal dispute with Creighton destroyed his experimental compounds in 1985. Mechanism is inferred from rat behavior only. Modern biohacker reports are mixed and small-N — some claim dramatic recall improvement, most report subtle-to-nothing. The single-source single-trial single-author profile is the worst-case pattern in nootropic evidence and Dylan's stated decision-shortcut explicitly excludes "single-source research without replication." A 4-week 5 mg PRN trial is mechanistically defensible if cost/safety are bounded (they are), but the honest verdict is WATCH-LIST, not OPTIONAL-ADD. Verdict would upgrade to OPTIONAL-ADD-PRN if a credible independent replication landed. Verdict would downgrade to SKIP-PERMANENT if vendor identity verification consistently fails or if a hepatotoxicity / cardiotox signal emerges in a structured biohacker dataset.

Mechanistically the most interesting next-gen orexin antagonist (OX2-selective, theoretically cleaner than DORAs for next-day cognition because OX1 reward/arousal circuits stay intact), and Phase 3 MDD3001 hit primary endpoints (May 2024 readout). But (a) NOT YET FDA-APPROVED, (b) not commercially available even gray-market, (c) Dylan does not have MDD or insomnia — he has a chronotype problem that orexin antagonism does not fix, and (d) daridorexant is the available DORA with comparable next-day-cognition profile. WATCH-LIST = re-evaluate at FDA approval (likely 2026-2027) and at first real-world Drugs.com user-rating cohort. Verdict would shift to STRONG-CANDIDATE for the depression-with-insomnia profile if approved AND priced reasonably; for Dylan-archetype it would only shift if (a) approved + commercial, (b) clinical evidence of cognitive-preservation advantage over daridorexant materializes, (c) PRN sleep escalation tool becomes needed.

Mechanistically novel and genuinely interesting (different pathway than the PPARδ/REV-ERB exercise-mimetic class), with strong 2023–2024 mouse data (Cell Metabolism 2024: ~70% endurance increase, fat loss in obese mice, heart-failure recovery). **But: zero published human data, zero registered human trials as of May 2026, and theoretical cancer concerns (ERRα is overexpressed in breast/colon/prostate tumors and drives Warburg-like metabolism — chronic agonism in tumor-permissive states is genuinely unsettled).** For Dylan: the exercise-mimetic angle is interesting on paper for MMA cardio, but he is **already a 20yo MMA athlete training daily** — his endogenous mitochondrial biogenesis signaling is already maximally engaged, and the rodent data is from sedentary/obese/diseased models where the headroom is biggest. Vendor sourcing is research-chem-only with very variable purity. **WATCH-LIST until** (a) any human Phase 1 reads out, (b) longer-term rodent oncology data clarifies the cancer risk, (c) independent labs replicate the endurance/fat-loss numbers. Would upgrade if human Phase 1 shows safety + biomarker signal; would downgrade to SKIP-PERMANENT if rodent oncology data shows tumor promotion.

Re-eval lift from prior SKIP — 2024-2025 data is genuinely interesting (SHARP cognitive trial in OSA, FOCUS Phase 3 ADHD success, NEJM Evidence shift work data), and 71% real-world preference over modafinil/armodafinil among switchers is a meaningful signal. But Dylan's PRIMARY-PICK is modafinil at $0.50-1.50/pill gray-market vs solriamfetol at $1,100-1,200/mo brand-only with no generic until ≥2031, and the BP-elevation profile is real (more pronounced than modafinil). Verdict would shift to STRONG-CANDIDATE if Dylan develops modafinil intolerance (rash, headache, anxiety) AND can secure US Rx via sleep specialist; would shift to OPTIONAL-ADD if FOCUS-style ADHD data replicates or off-label prescribing pathway opens.

Striking rodent potency story but zero modern human trials, no GMP supply, and reports of seizures/headaches at higher doses. The mechanism overlap with TAK-653 makes the clinical-stage compound the safer way to chase the same effect. Would upgrade to OPTIONAL-ADD only if (a) a human dose-finding trial appears, (b) a vendor with verified COAs emerges, and (c) the seizure question is resolved.

Phase 2 SAVITRI hit primary + secondary endpoints in inadequate-responder MDD, the safety margin vs convulsions is very large preclinically (1,017× AUC, 419× Cmax), and the TMS/cortical-excitability biomarker translated cleanly from rat to human — but every piece of human evidence outside trials is anecdotal vendor copy, the Phase 3 readout won't land for 2-3 years, and Dylan is (a) not depressed, (b) carrying a subconcussive-impact load that creates a nontrivial theoretical interaction with chronic AMPA potentiation. Verdict would upgrade to STRONG-CANDIDATE only after Phase 3 readout AND independent healthy-volunteer cognition replication; it would downgrade to SKIP-FOR-NOW if any seizure/excitotoxicity signal emerges in Phase 3 long-term safety data.

Mexico-approved + Phase 3 mature obesity data + interesting cognitive signal from triple-monoamine mechanism, but Dylan is 20yo, lean (185–190 lb), brain-dev concerned, and zero-caffeine baseline — meaning a long-half-life (~9 day) DAT/NET stimulant with cardiovascular load and ~9-day washout is a poor fit for daily use. Worth tracking as an OPTIONAL-PRN tool *if* a future use case emerges (cut-phase weight management, post-injury sedentary period, or specific high-cognitive-load campaign), but not a baseline candidate. Verdict would shift toward OPTIONAL-ADD if (a) Dylan's body comp goals shift toward serious cut, or (b) a later compound era with US approval + better safety profile lands.

Tα1 has the cleanest safety record of any immune-modulating peptide in this research base (>11,000 patients studied across 30+ trials, <1% serious adverse events, approved in 35+ countries for 30+ years), so the floor on harm is low. Confidence is MEDIUM-HIGH because: (a) for the indications it's approved for — chronic HBV, chronic HCV non-responder adjunct, sepsis-ICU adjunct, chemotherapy immune support, primary immunodeficiency — the evidence is A-tier, multi-decade, multi-country, FDA-orphan-designated; (b) for Dylan's actual likely use case — heavy-training-block immune support + acute illness recovery — the evidence is mostly **mechanistic extrapolation from approved indications + Castell-style post-marathon URTI immune-dip literature + peptide-clinic anecdote**, not direct sport-medicine RCT. Verdict is WATCH-LIST not STRONG-CANDIDATE because Dylan is a healthy 20yo with intact immune function — the marginal benefit is small in the absence of an active immune challenge. PRN-during-illness use is the highest-leverage application; reasonable to keep a vial on hand for cold/flu season or post-illness convalescence. Verdict would upgrade to OPTIONAL-ADD if Dylan develops chronic post-training URTI pattern (>3 colds in 3 months), gets an acute moderate-to-severe illness needing recovery support, or has a competition prep block where any immune dip is high-cost. Would upgrade further to STRONG-CANDIDATE if a sport-medicine immune-support RCT in trained athletes reads positive. Verdict would downgrade to SKIP-FOR-NOW only if a major safety signal emerged (none currently in 30 years of clinical use).

Thymulin is mechanistically elegant — endogenous thymic nonapeptide, zinc-dependent activation, cholinergic anti-inflammatory action via α7-nAChR potentiation, broad NF-κB/p38 inhibition, no toxicity at high doses in animal models — but the **clinical development gap vs Thymosin Alpha 1 is decisive**. Confidence is LOW-MEDIUM because: (a) the **A-tier human evidence base is essentially absent** — most data is rat, mouse, and cell culture; the few human-relevant trials are small French and Argentinian work in age-related immune decline and neonatal immunology from the 1980s-2000s, never replicated at modern scale; (b) thymulin requires zinc to function, so any "thymulin response" is partially conflated with zinc-status response — the marginal benefit over zinc supplementation alone is genuinely unclear; (c) the active analog PAT (thymulin-related peptide) carries most of the recent rat-pain-model literature, not native thymulin, so even the preclinical case is thinner than it appears; (d) sister peptide Thymosin Alpha 1 has 30+ years of clinical development, 35+ country approval, >11,000-patient safety dataset, and an FDA orphan drug designation — for any immune-modulation use case Dylan might have, **Tα1 is the dominant choice with strictly more evidence**. Verdict is WATCH-LIST low priority not OPTIONAL-ADD because Dylan-archetype healthy 20yo MMA athlete has no compelling indication where thymulin out-competes Tα1, zinc + Vit D adequacy, or simple sleep + recovery. Verdict would upgrade to OPTIONAL-ADD only in narrow scenarios: (1) a documented zinc-thymulin axis deficiency on testing (rare and not a routine clinical lab), (2) a chronic neuropathic pain indication where the α7-nAChR + spinal microglial mechanism becomes uniquely relevant, or (3) a future replicated human RCT that closes the evidence gap. Verdict downgrades to SKIP if a safety signal emerges (none currently, but the safety dataset is small enough that a moderate negative finding is plausible). For Dylan: **track the literature; don't buy or inject.**

Genuinely interesting α7 nAChR partial-agonist mechanism with PET-confirmed CNS occupancy at clinical doses (Hashimoto 2013) and a positive schizophrenia-adjunct trial improving P50 sensory gating and cognition (Shiina 2010, Zhang 2012); but healthy-young-adult cognitive evidence is essentially nonexistent (one PET binding study, no efficacy RCT in healthy adults), the α7 PAM/agonist class as a whole has been deeply scarred by encenicline's phase III failure for AD/schizophrenia cognition (forte trials, 2014-2016), 2014 EMA dose reduction post-arrhythmia signal, US sourcing is research-chem-only with quality risk, and Dylan's existing cholinergic stack (citicoline + planned alpha-GPC + planned ALCAR) covers the substrate side of α7 signaling at far lower regulatory and side-effect cost. Verdict shifts to OPTIONAL-ADD if (a) post-23andMe Dylan turns out to be a CYP2D6 normal/extensive metabolizer AND (b) emerging healthy-adult α7 PAM cognitive data firms up in 2026-2028 (TAK-071, ACD-856, or follow-on tropisetron healthy-volunteer work).

For Dylan, L-tryptophan is the strictly better choice — it preserves the TPH/IDO regulatory bottleneck that quality-controls serotonin synthesis, while 5-HTP overrides it and produces serotonin disproportionately in the periphery (GI, cardiovascular). 5-HTP's only real advantage is faster onset, and that gain is modest. Would shift to OPTIONAL-ADD only in a context where TPH/IDO is genuinely blunted (e.g., chronic high-CRP inflammation diverting tryptophan to kynurenines, or documented TPH2 loss-of-function variant) and a clinician is using 5-HTP tactically rather than chronically.

Re-research confirms ZERO peer-reviewed human or animal Adamax-specific studies exist (only inferences from Semax + P21 parents). Vendor copy contains material structural and historical contradictions. For Dylan's brain-priority profile, NA-Semax-Amidate covers the same use-case with vastly better evidence and identity-verifiable supply chain. Adamax becomes STRONG-CANDIDATE only if (a) a vendor produces a public batch-specific HPLC + MS COA matching the canonical sequence AND (b) Dylan has run a clean 4-week NA-Semax-Amidate baseline first.

For Dylan specifically (20yo, brain-priority, MMA athlete, no clinical ADHD diagnosis) the brain-development concerns + appetite suppression + dependence trajectory + lack of healthy-adult cognitive enhancement evidence make modafinil the cleaner pick. Verdict would flip to STRONG-CANDIDATE with a clinical ADHD diagnosis, or CONSIDER if modafinil + bromantane stack fails to deliver cognitive output after a fair trial.

A-tier rodent disease-modification data (cognitive deficits + amyloid + tau + neuroinflammation reverted, effect persisted 5 wk post-washout) is mechanistically exciting, BUT (a) zero clinical efficacy data in any cognitive-decline indication, (b) the sister sigma-1-only compound blarcamesine (ANAVEX 2-73) just had its EMA application recommended for refusal Dec 11 2025 — meaningful negative signal for the platform, (c) Phase 2 schizophrenia readout Oct 2025 was a safety primary endpoint with only "encouraging trends" on biomarkers, no efficacy hit, (d) human PK shows a 3.5-hr half-life that argues against simple translation of the rodent pulsed-dosing → 5-week-persistent-effect protocol, (e) research-chem availability is real (MCE, TargetMol) but priced for academic milligram screens, with no community dose, no community subjective base, no COA-verified human-grade vendor. Mechanism interesting; translation thin. Would upgrade to WATCH-LIST → OPTIONAL-ADD if (1) FTD orphan trial reads positive on cognition, or (2) Anavex's own M1-PAM thesis survives the blarcamesine EMA refusal and the sigma-1-platform stops looking like a stumble, or (3) a credible second-source replicates the rat 5-wk-persistence finding.

Modest cognitive effect size, slow onset (4-8 weeks for full effect), and better non-stim alternatives (modafinil) make it low priority for Dylan; only relevant if ADHD diagnosis emerges and non-stimulant is preferred over methylphenidate/amphetamines.

For Dylan-archetype, no specific use case justifies baclofen — he has no spasticity, no alcohol use disorder (zero alcohol baseline), and his anxiety baseline is already covered by V4 (theanine, magnesium, rhodiola). The off-label anxiolytic case is weak (B-tier at best, mostly extrapolated from AUD trials), and the abrupt-discontinuation withdrawal profile (delirium, seizure, autonomic instability — emergent within 1-4 days) makes casual or PRN use frankly dangerous compared to better-characterized alternatives. Verdict would change to OPTIONAL-ADD only if a specific medical indication emerges (post-injury spasticity, treatment-resistant alcohol craving, or severe anxiety unresponsive to first-line options).

For Dylan-archetype (20yo, peak natural T, brain-priority, MMA athlete on 185-190 lb / 6'0-6'1 frame, no aesthetic / mass goals stated as priorities) — boldenone is a B-tier body-comp tool from a class that's a SKIP-AT-20 across the board. Same family logic as testosterone-enanthate, methenolone, trenbolone: HPG-axis suppression at 20 risks permanent shutdown of an HPG axis still maturing; lipid (HDL crash + LDL/oxLDL rise), polycythemia (boldenone is among the most RBC-elevating AAS — clinically relevant hematocrit elevation is documented), and BP elevation are core signals; gray-market sourcing means QC variance + counterfeit risk; veterinary-grade injectables carry contamination concerns. MEDIUM (not HIGH) confidence because boldenone is genuinely milder than trenbolone or testosterone on the side-effect profile (less DHT-pathway, less aromatization, no neurosides) — if Dylan ever decides to run AAS post-30 with bloodwork backing, EQ is one of the more defensible Tier-2 picks. But "milder than tren" is not "good idea at 20." Aesthetic / mass goals are explicitly downstream in the priority stack, brain wins over body, and the appetite stimulation that's part of the EQ value proposition is irrelevant for a 185-190 lb athlete who's already hitting protein. Would change verdict only if Dylan reaches 28-30+, completes a final-state HPG / fertility checkpoint, has a documented competitive aesthetic goal, AND has measured baseline + monitoring plan.

Specifically for Dylan: no anxiety indication, so no reason to use. For anxiety-prone archetypes: STRONG-CANDIDATE — buspirone is the cleanest non-benzodiazepine anxiolytic with no abuse potential, no cognitive impairment, and no dependence. Fully reversible to OPTIONAL-ADD if Dylan's profile shifts toward anxiety. Distinct advantage: cognitively neutral (some weak pro-cognitive signals via 5-HT1A in PFC), unlike benzos.

Mechanism precision is very thin, evidence is thin Russian-only with zero Western replication, and the broader Khavinson short-peptide framework itself is contested — many cleaner liver-protection options (NAC, milk thistle, choline) cover the same use case with stronger evidence.

For Dylan at 20 — endogenous GH/IGF-1 axis is at lifetime peak, exogenous GHRH agonism on a peak-functioning HPS axis offers minimal upside, brain development still ongoing (IGF-1 is a developmental signal — chronically supraphysiologic levels during late-adolescent neurodevelopment have unknown long-term consequences), and the two indications a user would actually feel (recovery, body composition) are not Dylan's bottlenecks. Verdict is SKIP-FOR-NOW (revisit at 30+) rather than SKIP-PERMANENT because the drug isn't medically wrong-fit for him in the way retatrutide is — it just has no positive risk/reward at his current physiology. What would change verdict: age 30+ with declining IGF-1 on bloodwork, or post-MMA-career recovery problems that don't resolve with sleep/nutrition. MEDIUM confidence (not HIGH) because human PK data is solid but long-term safety data is essentially absent and the GH/IGF-1 oncology question remains theoretically open.

For Dylan at 20 — endogenous GH/IGF-1 axis is at lifetime peak. Stacking two pituitary stimulants on a peak-functioning HPS axis offers minimal upside, the recovery/body-comp benefits aren't his bottlenecks, brain still developing (chronic supraphysiologic IGF-1 during late-adolescent neurodevelopment uncharacterized), and pep-pedia community data shows the median user is 36-45yo (29%) with only 16% in the 18-25 cohort — this is a middle-age GH-restoration protocol being applied off-label by a young population. HIGH confidence (vs. MEDIUM for CJC-1295 alone) because the protocol-level question is even cleaner: combining two GH stimulants doesn't fix the absence-of-medical-need at 20, it amplifies it. What would change verdict: age 30+, documented declining IGF-1, recovery problem unresponsive to sleep/nutrition/training periodization. Revisit at 30+.

For Dylan-archetype (20yo, peak endogenous GH/IGF-1, MMA athlete with existing cubital-tunnel symptoms, brain-priority): exogenous GHRH agonism on a peak-functioning HPS axis offers no demonstrable upside; the DAC variant specifically trades pulsatility preservation (the gentlest argument for any GHRH analog at this age) for sustained continuous-style stimulation that flattens natural rhythm; chronic supraphysiologic IGF-1 during late-adolescent neurodevelopment is uncharacterized; GH-driven fluid retention worsens his existing ulnar-nerve compression risk (and DAC's sustained signal produces meaningfully more edema than sermorelin or no-DAC at comparable GH AUC); and the recovery / body-composition benefits aren't his bottlenecks. **HIGH confidence** (higher than the parent CJC-1295 entry's MEDIUM rating because the FDA 2024-09-27 Category 2 removal + December 2024 PCAC vote against 503A inclusion has now closed the cleanest legal access path, leaving only gray-market with documented quality variability — the regulatory signal is itself information about the risk/benefit calculus). Would change verdict if Dylan reaches 30+ AND develops documented GH-axis decline AND a recovery problem emerges that doesn't respond to behavioral/nutritional interventions — and even then, sermorelin or CJC-1295 (no DAC) would be the gentler first-line GHRH analog choice.

Same skip rationale as Ritalin IR — methylphenidate-class is a clinically valid ADHD treatment but Dylan does not have an ADHD diagnosis, and Concerta's defining feature (12-hour smooth coverage) is **actively bad** for a 20yo late chronotype migrating bedtime to midnight: an 8 AM dose is still therapeutically active at 8 PM, when wind-down for a midnight bedtime should be underway. Modafinil already owns the wakefulness/focus lane with a much cleaner sleep profile (12-15 hr half-life is real but the alerting effect plateaus and the second half is forgiving — methylphenidate's effect rises into the afternoon). Verdict would shift to STRONG-CANDIDATE only if (a) clinical ADHD diagnosis emerges from psychiatric eval, (b) modafinil + bromantane stack fails to produce sustained focus, AND (c) Dylan's chronotype has stabilized at midnight bedtime — even then, Focalin XR or Ritalin IR PRN would likely beat Concerta because they offer dose control Concerta's monolithic 12-hour shell does not.

Cerebrolysin owns this exact lane (porcine brain peptide hydrolysate, neurotrophic / anti-apoptotic claim, BBB penetration) with vastly more evidence — multi-decade Western + Russian + Chinese RCT base, CAPTAIN TBI trials, 2023 ESO stroke guideline mention, and an actual mechanistic story (BDNF/GDNF/CNTF mimetic activity, characterized peptide fractions). Cortexin has the same animal-cortex-hydrolysate concept but with a thinner B-tier Russian clinical dossier (stroke / encephalopathy / pediatric ADHD trials, mostly Khavinson-network), zero Western replication, zero ClinicalTrials.gov entries, and no characterization of which peptide(s) within the complex are actually doing anything. The "Khavinson family receptor-priming" framing some longevity protocols apply to Cortexin is unverified — the compound is sold and used in Russia primarily for neurology indications, not as a longevity primer, and the priming-receptor claim does not map onto any specific identified mechanism. **Skip for now in favor of Cerebrolysin** which delivers the same neurotrophic-cocktail thesis with substantially better evidence quality. Revisit only if (a) Dylan tolerates Cerebrolysin poorly and needs an animal-cortex-hydrolysate alternative, (b) independent Western replication of Cortexin's Russian stroke / pediatric trials publishes, or (c) a head-to-head Cortexin vs Cerebrolysin trial shows Cortexin non-inferiority.

At 20yo with no ADHD diagnosis, brain-development concerns dominate (animal data shows adolescent amphetamine exposure disrupts PFC dopamine axon growth via Netrin-1/DCC, male-specific). "Cleaner than Adderall" is mildly true but doesn't change the verdict — it's the same d-amphetamine that's in Vyvanse and the same compound class with brain-dev risk. Verdict flips to STRONG-CANDIDATE if Dylan gets a clinical ADHD or narcolepsy diagnosis with prescriber support.

At 20yo Dylan's endogenous DHEA-S is at lifetime peak (~age 20-25); exogenous supplementation is hormonally redundant and can perturb HPG axis with no upside. Would reconsider only if bloodwork (~June 2026) shows unexpectedly low DHEA-S — extremely unlikely at this age.

Massively-validated FDA drug for Alzheimer's, but the only halfway-decent healthy-young trial is Yesavage 2002 (n=18 pilots, single-domain, never replicated); the side-effect profile (GI, vivid dreams + insomnia from HS dosing, bradycardia/syncope, REM behavior disorder reports) is not justifiable for a 20yo with no cognitive deficit and a citicoline + alpha-GPC + (planned) modafinil + bromantane stack already covering the cholinergic + arousal axis. Verdict would only change if (a) a properly-powered healthy-young replication of Yesavage emerged with cleaner cognitive endpoints, or (b) Dylan developed a specific procedural-skill retention use case (rare).

At 20 with intact HPG axis, no hair loss, and no BPH, there is zero current indication. PFS risk + 5-week half-life + young age = wrong tool right now. Topical ru58841 is a safer first-line if MPB ever appears. Verdict flips to WATCH-LIST if visible MPB onset, and STRONG only after topicals fail in older user.

At 20yo with no documented hypogonadism, intervention is cosmetic/preemptive against an HPG axis that is already at peak natural function. Risk-benefit is unfavorable until June 2026 bloodwork establishes baseline. Verdict re-evaluates to STRONG-CANDIDATE *only* if total T < 350 ng/dL with low LH/FSH (i.e., true secondary hypogonadism), which is biologically unlikely at 20 absent obesity, head trauma, opioid use, or pituitary pathology — none apply to Dylan.

Same family rationale as parent Adderall analysis — for Dylan (20yo, brain-priority, MMA, no clinical ADHD diagnosis), the brain-development concerns + appetite suppression + dependence trajectory + lack of healthy-adult cognitive enhancement evidence apply identically here. Evekeo's 50:50 racemic split adds *more* peripheral noradrenergic load (HR/BP), which is strictly worse for a daily-cardio combat athlete. Brand-only US pricing (~$400/mo) makes the practical case still weaker. Verdict would flip to SAME-AS-ADDERALL (STRONG-CANDIDATE) only with a clinical ADHD diagnosis where the prescriber specifically wanted higher l-amphetamine ratio for clinical reasons — vanishingly unlikely scenario.

Lafon CRL-series compound that never advanced past 1970s-80s animal pharmacology — zero published human trials, zero established human safety profile, zero validated dosing. Modafinil is strictly better on every metric (cheap, abundant clinical data, established sourcing, known interactions). Verdict would change only if (a) someone publishes an actual human PK/PD study on fladrafinil AND (b) modafinil sourcing collapses globally — currently inverted.

For Dylan's daily-driver question, modafinil dominates Focalin on every axis (lower brain-dev risk, lower abuse liability, no Schedule II logistics, longer effective duration, vastly better sourcing). Focalin remains a legitimate PRN-tool tier OPTIONAL pick — methylphenidate-class is the lowest-brain-dev-risk classical stimulant — but is not warranted before modafinil has been tried and either failed or hit a ceiling. What would change the verdict: (1) clinical ADHD diagnosis after baseline workup, (2) modafinil non-response or intolerance after 8-12 weeks, (3) specific high-output day where the sharp-focus stimulant signature outperforms eugeroic mechanism.

Strong animal hypertrophy signal but failed clinical program (Acceleron ACE-031 cardiac/vascular safety halt, ACE-083 missed efficacy endpoints), thin healthy-adult human evidence, and peptide-vendor identity is questionable for a 30+ kDa glycoprotein that almost certainly cannot survive subQ injection intact. Verdict could shift if a gene-therapy trial demonstrates clean safety in healthy adults or if a credible non-glycosylated peptide mimetic emerges with proper COA chain.

Mechanism is robust (Belgian Blue cattle, double-muscled mice, primate AAV1-FS344 trials all confirm myostatin blockade → hypertrophy), but human evidence for *injectable peptide* FS-344 is essentially zero — the dramatic results (Mendell 2015 Becker MD, Kota 2009 primates) all came from AAV gene therapy providing sustained expression, NOT subQ peptide injection with a 90-min half-life. For Dylan at 20yo with peak natural muscle growth potential, this is unjustified anabolic risk-stacking against a glycoprotein vendors almost certainly cannot synthesize bioactively. Verdict shifts only if (a) credible engineered FST-Fc variant reaches clinical-grade availability, or (b) Dylan develops a muscle-wasting indication.

Mechanism (adenylyl cyclase → cAMP → CREB → BDNF) is real and elegant, but human cognitive RCTs are essentially nonexistent — the LTP/memory story rests on hippocampal slices and rodent models. Body-comp marketing is industry-funded and weakly replicated. Dylan already has better cAMP/BDNF tools planned (bromantane, Semax/Adamax, Cerebrolysin) that come with actual human evidence. Would upgrade to OPTIONAL only if (a) a credible human cognitive RCT emerges, or (b) Dylan develops a specific use case (older relative, glaucoma, etc.).

For Dylan at 20 — same core "no marginal benefit at peak natural GH/IGF-1 axis" rationale as ipamorelin/CJC-1295, plus an additional layer: GHRP-2's cortisol + prolactin spillover is a categorical disadvantage versus the cleaner selective GHRP (ipamorelin) for any user who would actually consider this class. The hierarchy is: in young healthy users, no GHRP needed; in users where one is appropriate, ipamorelin replaces GHRP-2 on every dimension except raw GH-pulse magnitude (which is rarely the limiting factor). MEDIUM rather than HIGH because the 30+ longevity-clinic context where some operators still prefer GHRP-2's stronger pulse is genuine — not relevant for Dylan but the compound has a non-zero use case. Verdict moves to SKIP-PERMANENT only if Dylan stays untested-amateur indefinitely with no career path involving sanctioned testing AND we confirm ipamorelin dominates on his future use cases (which it does on first principles).

At 20 with peak HPG/HPS axes, exogenous GH-axis stimulation has no meaningful upside — and GHRP-6 is the dirtiest GHRP in the family on the spillover axis (cortisol, prolactin, aldosterone) plus brings the strongest appetite stimulation, which Dylan does not need. Effectively obsolete: anyone considering GHRP-class agonism in 2026 should use ipamorelin (cleaner) or GHRP-2 (stronger GH pulse) — GHRP-6's only remaining niche is bulking-phase appetite stimulation in older lifters with low food drive, which is irrelevant here. Verdict moves to OPTIONAL only at 30+ AND with documented poor appetite during bulking, AND if ipamorelin's cleaner profile is somehow inadequate — a narrow scenario that almost never wins on a head-to-head.

For Dylan-archetype, guanfacine is **directionally wrong** — it is sedating, anti-alertness, BP-lowering, and works against the wakefulness/output goals of his V5 stack. The Arnsten α2A-PFC mechanism is real and elegant, but the clinical evidence for cognitive enhancement in healthy adults is thin (1 small positive trial 1999, 1 null trial 2005, null in older adults 2018), the indication is ADHD adjunct or PFC-impaired populations, and the side-effect bill (sedation 36%, fatigue 20%, orthostatic hypotension, bradycardia) is unattractive for a healthy 20-year-old whose limiter is "stay alert and output for 6-12 hr." Verdict would change to OPTIONAL-ADD only in a future ADHD-adjunct context with formal Rx (e.g., if Dylan ever gets a formal ADHD diagnosis and goes on stimulants but needs evening sleep onset / impulsivity damping). For general cognitive enhancement: skip.

Highest-amplitude GH pulse in the GHRP family but the fastest tolerance buildup (somatotroph desensitization in 2-3 weeks of daily dosing) and dirty hormone-spillover profile (cortisol/prolactin elevation comparable to GHRP-2). For Dylan at 20 with peak endogenous GH/IGF-1, all three downsides land — peak baseline means no marginal GH benefit, fast tolerance means the compound self-destructs, and CD36 cardioprotection has no relevance to a healthy 20yo. The CD36 cardiac angle is mechanistically real but only matters in older or post-MI populations and remains animal-only. Verdict moves to WATCH-LIST experimental for cardiac-protection applications at 50+ if human cardiac outcomes ever validate; for GH purposes, ipamorelin or CJC/ipamorelin combo dominates.

For Dylan-archetype (20yo, peak endogenous GH/IGF-1 axis, MMA athlete, brain-priority) — exogenous HGH on a peak-functioning system is the single clearest "wrong drug, wrong patient" call in the GH-axis class. Direct GHR agonism bypasses every feedback loop the GHRH analogs and secretagogues at least partially preserve; supraphysiologic IGF-1 elevation is essentially guaranteed at any meaningful dose; all the same mechanistic concerns that drive SKIP-AT-20 for sermorelin/CJC-1295/MK-677 (peak natural baseline, late-adolescent neurodevelopment, fluid retention worsening cubital tunnel) apply with greater magnitude because HGH produces a larger and more sustained GH/IGF-1 surge than any upstream secretagogue. Plus: the long-term safety record of supraphysiologic GH exposure in healthy adults is the worst in the GH-axis class — Liu 2007 Annals meta-analysis documented significant increase in adverse events (edema, carpal tunnel, glucose intolerance) without clinically meaningful body-comp benefit; the Rudman 1990 NEJM paper that birthed the entire anti-aging-clinic industry was n=12 over 6 months and never showed mortality or longevity benefit (Rudman himself died at 67 of complications related to his own research subject participation). HGH is also unambiguously criminalized for off-label distribution (21 USC § 333(e)). The ONLY archetypes where HGH is appropriate are documented adult or pediatric GH deficiency on bloodwork (STRONG-CANDIDATE under endocrinology supervision), HIV wasting / cachexia, and FDA-approved indications. For 20yo healthy peak-axis Dylan, this is the most decisive SKIP in the whole GH-axis branch — HIGH confidence (vs. MEDIUM for CJC-1295, MEDIUM-HIGH for sermorelin and MK-677). Would NOT change verdict at 30+ unless documented adult-onset GH deficiency on stim test (insulin tolerance test or glucagon stim) — sermorelin/tesamorelin/CJC + ipamorelin are far better risk/reward for general age-related GH decline; HGH belongs reserved for genuine deficiency or specific FDA-approved indications.

Cognitively interesting class with a real mechanism (BDNF upregulation, hippocampal LTP enhancement), but IDRA-21 specifically has zero modern human safety data and is sold only via research-chem channels with no COA standardization. The credible ampakine candidates for human use have moved to TAK-653 / NBI-1117568 / org-26576 in clinical trials — IDRA-21 is mostly a 1990s relic. Would upgrade to WATCH-LIST if a credible vendor with COAs emerged AND TAK-653 access stalled; would upgrade further only with at least one human dose-finding study.

Supraphysiologic IGF-1 in a 20-year-old with peak endogenous IGF-1, plus mitogenic/cancer signaling concern, plus severe-hypoglycemia risk, plus brain-development concerns (IGF-1R is active in adult neurogenesis but supraphysiologic dosing is unstudied in young healthy men) = clear net-negative. Verdict would change ONLY for documented severe primary IGF-1 deficiency (Laron syndrome / SPIGFD) — biologically incompatible with Dylan's profile.

Same SKIP-AT-20 rationale as parent IGF-1, *amplified* by LR3's pharmacokinetic profile — long half-life + IGFBP evasion = sustained supraphysiologic free IGF-1, which is exactly the exposure pattern most strongly linked to permissive cancer signaling, acromegalic-pattern soft-tissue overgrowth, and severe hypoglycemia. For Dylan at 20 with peak endogenous IGF-1 (~250-400 ng/mL typical), no body-comp gap, brain still maturing through mid-20s, and brain-priority ranked above all else — there is zero benefit case. Verdict reverses ONLY for documented severe primary IGF-1 deficiency under endocrinology supervision (and even then, native rhIGF-1 / Increlex is the appropriate molecule, not LR3).

Cleanest of the GHRP family on the hormone-spillover axis (no cortisol/prolactin spike), but for a 20yo at peak natural GH/IGF-1 the marginal endogenous-GH-pulse benefit doesn't justify HPG/somatotrophic axis perturbation, glucose modulation risk, or WADA exposure. Same logic as CJC-1295. Verdict moves to OPTIONAL-ADD only at 30+ with declining recovery, sleep architecture changes, or documented low IGF-1 — and even then, behavioral GH levers (deep sleep, training, fasting) come first.

Isotretinoin is the most powerful systemic acne therapy ever developed (~80%+ long-term remission of severe nodulocystic acne in landmark Layton 1993 + multiple subsequent meta-analyses), but for Dylan's specific situation — perioral dermatitis around the nose and tinea cruris, no severe nodulocystic acne — it is wildly disproportionate first-line. POD (perioral dermatitis) responds to behavioral fixes + topical metronidazole / azelaic acid / pimecrolimus + oral tetracyclines in >90% of cases; tinea cruris is fungal and isotretinoin doesn't address it at all. For a 20yo MMA athlete with brain priority, the off-label low-dose isotretinoin protocol for recalcitrant POD (5-10 mg/day, used by some dermatologists when topicals + tetracyclines fail) is **theoretically on the table** but only as a third- or fourth-line move after dermatologist supervision. The two specific deal-breakers that keep this SKIP-FOR-NOW: **(1) the depression / suicidality black box warning**, controversial in literature (some cohort studies show RR ~1.5; others null; 2024 Cochrane more reassuring) but a real risk for someone with brain-priority self-experimentation profile, and **(2) arthralgia + myalgia** at typical doses, which is a meaningful problem for an MMA athlete (musculoskeletal stiffness, reduced exercise tolerance, theoretical increased injury risk). Would upgrade to STRONG-CANDIDATE if Dylan develops actual moderate-to-severe nodulocystic acne resistant to topicals + oral tetracyclines. Would consider WATCH-LIST low-dose only if perioral dermatitis becomes truly recalcitrant after a properly run dermatologist-supervised protocol of behavioral fixes + topical metronidazole + oral doxycycline 50-100 mg/day for 6-8 weeks.

Middle-of-the-road DORA — beat zolpidem-ER on objective sleep onset in SUNRISE-1 (the cleanest head-to-head DORA-class win) and has the strongest sleep-onset signal in the 2025 NMA, but the 17-19 hr half-life is the WRONG direction for a 20-year-old late chronotype who needs the drug fully cleared before training the next morning. Dylan's pharmacological sleep escalation tool, if ever needed, should be daridorexant (8 hr half-life). Verdict shifts to STRONG-CANDIDATE only if (a) sleep-onset latency is the dominant complaint (not WASO), (b) daridorexant is unavailable or insurance-blocked, AND (c) Dylan can tolerate 1-2 weeks of mild morning fog during adaptation.

HPG-axis suppression in still-developing 20yo endocrine + brain-development concerns + documented hepatotoxicity case reports + FDA prohibited + research-chem product identity questionable. Nothing about Dylan's stated priorities (brain #1, MMA performance) is meaningfully advanced by a body-comp anabolic. Verdict would change only at age 30+ with bloodwork-supported HPG recovery plan, post-cycle therapy access, and verified product COA — and even then the evidence/risk ratio is poor vs alternatives.

NAC 1200 mg + glycine in V4 already drives endogenous GSH synthesis with stronger evidence base and lower cost; liposomal GSH addresses GI bioavailability but not BBB delivery, and the brain protection thesis is the priority. Verdict would flip if a chronic-NAC failure profile emerges (no objective GSH/oxidative-stress improvement on bloodwork) or if a credible RCT lands showing CNS GSH elevation from oral liposomal GSH.

Direct dopamine receptor agonism carries class-warning impulse-control-disorder (ICD) risk — pathological gambling, hypersexuality, compulsive shopping/eating — at population rates of 2.8-8% in PD patients, and the receptor-level mechanism does not care whether the user is 70 with PD or 20 with a developing prefrontal cortex. Lisuride is the cleanest ergoline on the cardiac axis (5-HT2B antagonism actively prevents valvulopathy that killed pergolide and benched cabergoline) but cleanness vs. its ergoline siblings is irrelevant when the question is whether a 20-year-old MMA athlete should be a chronic direct DA agonist user. Verdict would change to OPTIONAL-CONSIDER if Dylan develops a prescriber-managed Parkinson's-adjunct context (he won't), or to WATCH-LIST if a credible PK-tuned microdose protocol with prospective ICD monitoring emerges in the biohacker literature (none exists — current biohacker use is anecdotal Ray-Peat-forum off-label and mostly for prolactin lowering, which Dylan does not need).

Two converging lines of evidence make this a clean SKIP for Dylan at 20: (1) the placebo-controlled microdose RCT literature (de Wit, Hutten, Szigeti, Bershad 2019) is mostly null or expectancy-driven once blinding is enforced — the Yanakieva 2018 positive signal has not held up to subsequent rigorous replication, and (2) macrodose use in a still-developing 20yo prefrontal cortex with no treatment-resistant indication is hard to justify against the Schedule I legal exposure, HPPD risk, valvulopathy theoretical concern at chronic micro use (5-HT2B partial agonism), psychosis-precipitation risk in undiagnosed family history, and dangerous interaction with lithium (seizure reports) + serotonergic drugs. Documented for completeness; not a daily nootropic and not a defensible recreational tool at this life stage. Would only revisit at age 25+, after brain maturation, with a documented clinical indication (treatment-resistant depression, end-of-life anxiety, AUD), under a DEA-licensed clinical trial or regulated psilocybin/MDMA/ketamine analog program — and even then this is not the molecule of first choice given Schedule I friction.

Cosmetic-AAS archetype with zero modern clinical evidence base for healthy adults — entirely a bodybuilding "show prep hardening" compound used in low-body-fat states for aesthetic vasculature/dryness. No cognitive, athletic-performance, recovery, or longevity case. Same-family AAS skip-at-20 logic applies: HPG suppression during ongoing axis maturation (peak HPG at 20yo), atherogenic lipid changes (DHT-class HDL crash without E2 protection — non-aromatizing makes lipid profile worse on this dimension), accelerated androgenic alopecia in genetically predisposed users (potent peripheral androgen, no 5α-reductase protection because already DHT-class), gray-market supply chain with high counterfeit rates. For Dylan (20yo MMA athlete, brain-priority, no contest-prep aesthetic goal), Masteron addresses no problem he has and produces no benefit he wants. Verdict reverses ONLY for older bodybuilder in active contest preparation with documented medical supervision — irrelevant to Dylan now or ever (combat sport ≠ bodybuilding aesthetics).

Wrong tool for Dylan's brain-priority + MMA stack. Limited use case (cosmetic tanning + sexual function), receptor-promiscuous side effect profile dominated by nausea + spontaneous erections + nevus darkening that materially complicates melanoma surveillance — a fundamental dermatologic concern with no easy mitigation in a 20yo with limited UV exposure history. Verdict would shift to OPTIONAL-WITH-CAVEATS only if Dylan specifically prioritized year-round tan and accepted dermatology baselining + 3-6 month surveillance commitment. For sexual function specifically, FDA-approved bremelanotide (PT-141) is the better tool with cleaner receptor selectivity.

AAS at 20 — even "mild" DHT-derivatives suppress HPG axis and risk durable endocrine harm during late puberty/HPG maturation; reputation as "clean" is mostly relative to harsher AAS, not absolute; expensive + heavily counterfeited makes risk/reward worse than oxandrolone if AAS were ever justified.

Methylin is the Mallinckrodt brand name for generic methylphenidate IR — pharmacokinetically and clinically identical to Ritalin IR. Verdict tracks parent file (ritalin.md) one-for-one. SKIP-FOR-NOW for Dylan's daily question because (1) modafinil dominates as first-line at 20yo, (2) within MPH-class Focalin (d-isomer-only) is the cleaner version of this exact drug, and (3) Schedule II Rx access is gated. **OPTIONAL-ADD as PRN tool** if clinical ADHD diagnosis ever opens Rx access. The only Methylin-specific differentiator is its **chewable tablet + oral solution formulations** (pediatric-friendly liquid/chewable), which have minor practical advantages for patients who can't swallow pills but no relevance for Dylan. **Refer to ritalin.md as the canonical methylphenidate-IR file.**

Dylan has no MPB at 20. Minoxidil is a treatment for active androgenetic alopecia (or refractory hypertension), not a preventive optimization — there is nothing to prolong-anagen on, no miniaturization to reverse. Verdict flips to STRONG (topical first) on visible MPB onset, and OPTIONAL combo with finasteride/dutasteride/ru58841 if MPB becomes aggressive. Oral LDOM moves to STRONG only if topical fails or is intolerable.

Mirtazapine's primary clinical effects (sedation, appetite stimulation, +2-10 lb weight gain in 3-6 months) are direct inversions of Dylan's MMA performance + body-composition + cognitive-output goals. Verdict would only flip to OPTIONAL-ADD if Dylan develops clinical depression with comorbid insomnia + appetite loss, in which case mirtazapine becomes a tier-1 Rx specifically because of the same effects that disqualify it now. No nootropic case; no chronotype-migration case; no off-label use that survives the cost-benefit for an athlete.

For Dylan at 20 — endogenous GH/IGF-1 axis at lifetime peak; sustained tonic GH/IGF-1 elevation (vs. natural pulsatile pattern) has unfavorable risk/benefit on a peak-functioning system; appetite increase is directly counterproductive for combat-sport weight management; documented A-tier glucose intolerance and edema at chronic dosing; congestive heart failure cases in older Phase 3 trials (frail elderly, but signal exists). Strong-candidate at 30+/40+ for sarcopenia or recovery-decline contexts. What would change verdict: 30+ age + bloodwork showing declining IGF-1 + body-composition decline that doesn't respond to standard interventions + accepted oral-pill convenience tradeoff vs. injectable CJC/ipamorelin combo. MEDIUM-HIGH confidence (higher than CJC-1295's MEDIUM) because the MK-677 evidence base is genuinely larger (Phase 3 trials in elderly + multiple healthy-adult RCTs) and the side-effect profile is more empirically characterized — i.e., we know more about what it does and don't, and the picture is less favorable for a young athlete than for a sarcopenic older user.

Recreational dissociative profile with no cognitive use case; theanine + magnesium + tryptophan/glycine cleaner for sleep/anxiety; gummy market is a vendor lottery with documented adulteration, hospitalizations, and deaths (Diamond Shruumz 2024).

Same MAS chemical as Adderall plus a 16-hour duration that is uniquely incompatible with Dylan's late chronotype (sleep onset destruction is the central differentiator from IR/XR) — confidence is HIGH (rather than MEDIUM like parent Adderall) because the duration mismatch alone is a categorical disqualifier independent of the parent skip rationale. Verdict would flip only with a clinical ADHD diagnosis AND a chronotype that tolerates 16-hour stimulant exposure.

Wrong compound at the wrong time for Dylan — mechanism is interesting (the only non-direct-agonist way to raise NMDA-glycine-site tone, theoretically activity-dependent and therefore safer than direct agonists), but human evidence in healthy adults is essentially zero, the development program has been stalled at Phase 2 since ~2010-2015 with no public readout of cognitive endpoints, anecdotal corpus is one or two YouTube reviews and no real Reddit/forum body, and stacking a novel NMDA-glycine PAM with TAK-653 (AMPA PAM) was already flagged in the encyclopedia as too aggressive (two unproven glutamate enhancers). Verdict would upgrade to WATCH-LIST if Rottapharm/successor publishes Phase 2 cognitive data with cleanly positive MATRICS/PANSS-cognition signal AND independent lab-grade COA-verified vendor product becomes routine; would upgrade to OPTIONAL-ADD only after FDA-pathway revival or replication by an unaffiliated group; would stay SKIP-FOR-NOW if no further development announcements appear by 2027.

At 20yo with peak natural HPG axis, AR-axis modulation is gratuitous; ostarine's documented HPG suppression (less than LGD-4033 but still real and dose-dependent), unresolved hepatotoxicity case-report signal, and complete absence of long-term safety data in young eugonadal men make this a textbook risk-stack-without-need scenario. Combined with research-chem-only sourcing (FDA-prohibited supplement channel + counterfeit/contamination-prone gray market), the appropriate verdict is firm SKIP. Verdict would not change pre-25 absent unforeseen indication; would re-evaluate post-25 only with documented anabolic-deficient state and validated pharmaceutical-grade source.

Same-family logic to all anabolic-androgenic steroids skip-at-20 cluster. Even the "mildest" AAS reliably suppresses the HPG axis in young eugonadal males at typical bodybuilder doses (20-50mg/day), produces marked atherogenic lipid changes (LDL up, HDL crash), and obligately stresses the liver via 17α-alkylation. For Dylan at 20yo with peak endogenous testosterone (~600-900 ng/dL typical), no documented hypogonadism, and brain-priority + longevity orientation, the risk constellation (HPG suppression with potential post-cycle anhedonia / mood crash, atherogenic dyslipidemia, hepatotoxicity, modest body-comp upside that's achievable through training + nutrition + creatine alone) is straightforwardly unfavorable. Verdict reverses ONLY for documented severe catabolic medical indication (HIV wasting, >40% TBSA burn, severe trauma) under endocrinology / burn-unit supervision — clinically implausible for Dylan.

Three converging reasons to skip: (1) the entire intranasal-oxytocin literature is in a replication crisis — most early "trust / social cognition / pro-social" findings (Kosfeld 2005, Baumgartner 2008, Domes 2007) have failed independent replication (Lane 2016 meta, Walum 2016, Nave 2015 review); (2) actual CNS bioavailability after intranasal dosing is mechanistically uncertain — Leng 2016 (Biological Psychiatry) shows the nasal-to-brain pathway may deliver far less peptide centrally than the field assumed, with most subjective effects possibly placebo or peripherally mediated; (3) for Dylan's specific use cases (sales calls, sparring, content creation), Selank covers the anxiolytic axis with vastly better evidence, and propranolol covers somatic performance anxiety — oxytocin adds no incremental value those tools don't already provide. Verdict-confidence is MEDIUM-LOW (not LOW) because true effects probably exist at smaller magnitudes than original claims, with substantial trait × context × sex moderation, so the compound isn't "fake" — it's just not a good investment for Dylan right now. Verdict would upgrade to WATCH-LIST if pre-registered Western RCTs in Dylan-archetype (young, healthy, performance contexts) emerge with effect sizes worth chasing; would NOT upgrade based on more anecdote.

Mechanism is plausible and mechanistically distinct from mature IGF-1 (less mitogenic systemic signaling, more local satellite-cell focused); the 2011 Kandalla landmark paper specifically positioned MGF as combating sarcopenia "without IGF-1 oncogenic side effects." But human RCT evidence is essentially absent — the case rests on in vitro + rodent + rabbit models. For a 20yo MMA athlete with peak endogenous satellite-cell function, intact natural MGF response to eccentric loading, and BPC-157/TB-500 already pursued for cubital tunnel, PEG-MGF adds gray-market injection burden + theoretical IGF-axis exposure for a marginal hypothetical recovery delta. Verdict would shift toward OPTIONAL only with (a) documented sarcopenia/wasting state (impossible at 20yo healthy) or (b) significant chronic injury that BPC-157 + TB-500 + sleep + nutrition cannot resolve. MEDIUM rather than HIGH because the safety case is genuinely better than mature IGF-1 LR3 — just not justified for this profile.

For Dylan-archetype, modafinil owns the wakefulness lane at ~$0.50-1.50/pill gray-market with 25+ years of safety data and a much better cognitive enhancement signal in healthy adults; pitolisant at $4,300+/mo brand-only with effectively zero gray-market footprint, an 8-week titration to clinical effect, and **no published cognitive enhancement data in healthy non-EDS adults** is a poor fit as a primary play. Verdict would shift to STRONG-CANDIDATE if Dylan develops modafinil intolerance (rash/SJS watch, persistent headache, anxiety) AND secures US Rx via sleep specialist with insurance/copay program, OR if a narcolepsy/IH diagnosis emerges. Re-eval lift from prior implicit "bad side effect profile + thin cognitive evidence" framing in encyclopedia: **the side-effect profile is actually favorable** (rates comparable to placebo in the 2025 meta-analysis), but the **thin cognitive evidence in healthy adults stands** — pitolisant's wake-promotion is well-supported, but cognitive lift is wakefulness-derived, not direct cognitive enhancement. Verdict softened from "SKIP" to "SKIP-FOR-NOW" with explicit triggers for re-eval.

PPAP is the first CAE compound and a historical-mechanistic milestone, but its successor BPAP is ~130× more potent in vivo (full antagonism of tetrabenazine depression at 0.05 mg/kg vs PPAP's 2.5 mg/kg), enhances serotonin in addition to catecholamines, and is the actively-researched compound in this family. For Dylan-archetype the rational move at this CAE-class slot is BPAP if the watch-list moves to active, OR low-dose selegiline (which has 40+ years of human data and Rx access) if MAO-B inhibition is also wanted. PPAP has zero unique value vs BPAP and zero human RCTs. Would re-evaluate ONLY if BPAP sourcing collapses AND a human PPAP trial emerges — not expected.

Solid A-tier evidence for pediatric + adult ADHD, but no evidence for cognitive enhancement in healthy adults — same logic as atomoxetine. Non-stim ADHD niche only; subjective profile is subtle, weeks for onset, and side effect surface (somnolence, suicidal-ideation black box) is meaningfully worse than modafinil/bromantane/Adamax/Semax for Dylan's brain-priority cognitive-output use case. Verdict would change only if Dylan received a formal ADHD diagnosis with explicit non-stim preference.

Most HPG-suppressive of common SARMs + hepatotoxicity case reports + brain-priority profile makes endocrine disruption a non-starter at 20yo; would change only with clean long-term human data and verified COA-tested supply (neither exists).

Modafinil is preferred at 20 (cleaner mechanism, lower brain-dev risk, daily-safe). MPH-class beats amphetamine class on developmental concerns, but Ritalin specifically is dominated by Focalin (cleaner d-isomer-only) within the class. Verdict flips to STRONG-CANDIDATE if Dylan ever gets a clinical ADHD diagnosis and Rx access — at that point cheap generic IR is a reasonable second-tool-in-pocket.

Off-label cognitive use is supported by two real human RCTs (Van Duinen 2018 episodic memory in healthy elderly; Gilleen 2018 schizophrenia adjunct) but the catalytic-site, non-subtype-selective binding produces nausea/diarrhea/weight loss in 10-20% of users — the same problem that killed rolipram. For Dylan-archetype: BPN14770 (allosteric PDE4D NAM, primate-specific binding pocket) is the cleaner version of this exact mechanism, already documented on the wiki, and that's where the cognitive-PDE4 thesis should live until/unless a topical or subtype-selective replacement emerges. Verdict would not change without a healthy-young-adult cognitive RCT showing tolerable risk-benefit at chronic dosing.

Dylan has no documented hair loss at 20 with peak HPG axis function. RU58841 is a hair-loss intervention, not a preventive optimization, and the human safety dataset is thin enough that running it without indication is buying tail-risk for zero benefit. Verdict moves to OPTIONAL-ADD if any visible MPB onset occurs (recession at temples, vertex thinning, Hamilton-Norwood ≥II), and to STRONG-CANDIDATE if Dylan ever experiences post-finasteride/dutasteride sexual or mental side effects and needs a local-only AR antagonist option.

NAC at 1200 mg/day already in V4 supplies the rate-limiting cysteine substrate for endogenous GSH synthesis at lower cost and with stronger replicated brain evidence; SAG's incremental advantage over NAC at the brain is theoretical and direct cognitive RCTs are absent. Confidence is LOW because (a) SAG's oral bioavailability advantage over plain GSH is real (Fanelli 2018, Cai 2022), (b) liposomal GSH out-performs SAG on some peripheral GSH markers, and (c) a credible scenario exists where NAC fails and a direct-GSH delivery route (SAG or liposomal) becomes useful. Would re-evaluate if Dylan's NAC-on bloodwork shows persistent oxidative-stress markers (low GSH/GSSG, elevated 8-OHdG, elevated F2-isoprostanes), if a specific GSH-deficiency genetic signal lands (GCLC/GCLM/GSTM1-null), or if direct human cognitive-endpoint RCTs on SAG read out positive.

Strong, replicated A-tier evidence as a schizophrenia adjunct (Tsai 2004, Lane 2008, multiple meta-analyses) for negative symptoms + cognition when added to non-clozapine antipsychotics. Essentially zero healthy-adult cognitive evidence — the entire clinical literature is built on patients with NMDA hypofunction, a condition Dylan does not have. The mechanism is inherently a "fix what's broken" tool rather than a "push above baseline" tool, because the NMDA glycine site is approximately saturated in healthy adults under normal conditions (same logic as oral glycine — see glycine.md). Verdict would shift to WATCH-LIST only if a credible RCT in healthy young adults showed cognitive benefit independent of the schizophrenia population (none currently exists and none is expected, as the mechanism predicts null effect in saturated systems). For Dylan: no indication, no reason to trial.

Wrong-fit profile for Dylan at 6'0-6'1, 185-190 lb athletic — appetite suppression + ~40% lean-mass-loss-fraction documented for the class actively counters MMA fueling and protein needs. SKIP-FOR-NOW (not SKIP-PERMANENT) because plausible future scenarios reopen the question — significant weight gain past athletic career, T2D diagnosis, or established CV risk would all flip the verdict. The drug is genuinely best-in-evidence-class for its actual indications; verdict is about Dylan's profile, not the drug.

For Dylan-archetype (20yo, peak endogenous GH/IGF-1, brain-priority, MMA athlete with existing cubital-tunnel symptoms) — sermorelin is mechanistically the gentlest GHRH analog (preserves pulsatility better than CJC-1295 DAC, shorter exposure than tesamorelin, smallest receptor-desensitization risk), but the indication doesn't apply: peak natural GH baseline means agonism on a peak-functioning system has no demonstrated upside, late-adolescent neurodevelopment + chronic supraphysiologic IGF-1 elevation is uncharacterized, GH-driven fluid retention worsens nerve-compression risk (cubital tunnel relevance), and the recovery / body-comp benefits aren't Dylan's bottlenecks (sleep + nutrition + training periodization are). MEDIUM-HIGH confidence (higher than CJC-1295 because sermorelin's pediatric-GHD pharmacology is well-characterized from 1990-2008 and the safety profile is the cleanest in the GH-axis peptide class) but the same SKIP-AT-20 reasoning applies. Would change verdict if Dylan reaches 30+ AND develops documented GH-axis decline (low IGF-1 on bloodwork) AND a recovery problem emerges that doesn't respond to behavioral/nutritional interventions. The older anti-aging clinic context is a different patient population: at 50+ with declining GH baseline and metabolic creep, sermorelin moves to OPTIONAL-ADD because the risk/reward profile shifts.

First DORA approved (2014, Merck), most real-world data and longest tail of post-market evidence — but the 12-hour half-life produces measurably more next-day grogginess than daridorexant's 8 hr, and the 2025 network meta-analysis ranked it weakest of the three approved DORAs on subjective TST. Dylan does not have insomnia (chronotype problem, not sleep-onset problem), and if a DORA is ever needed, daridorexant is the better-fit tool for a brain-priority 20yo. Verdict would shift to OPTIONAL only if (a) daridorexant becomes unavailable or unaffordable, (b) a sleep-maintenance indication emerged where suvorexant's longer half-life is actually wanted, or (c) the long-term amyloid-clearance signal (Lucey 2023) gets replicated and a 20-year prevention case opens up.

Cerebrolysin already owns Dylan's neuroprotection lane with multi-decade RCT data; Synapsin's combined-blend evidence is laboratory-only with zero published human RCTs on the formulation — adding it on top of Cerebrolysin is mechanism-stacking without evidence. Confidence is LOW because the underlying Rg3 + NAD+-precursor mechanisms are individually plausible (TBI rodent data is real), Synapsin-specific evidence might emerge, and it could become a reasonable Cerebrolysin alternative if EU sourcing breaks. Would re-evaluate if: (a) any human RCT on the compounded blend reads out positive, (b) Cerebrolysin sourcing fails and Dylan needs an at-home, needle-free neuroprotection proxy, or (c) Dylan develops needle aversion that compromises Cerebrolysin adherence.

For Dylan-archetype (20yo, peak endogenous GH/IGF-1, brain-priority, MMA athlete, 185-190 lb on 6'0-6'1 frame with no visceral adiposity) — tesamorelin is the cleanest GH-axis peptide in its class (preserves pulsatility, FDA-approved, best-characterized safety profile, real RCT visceral-fat data) but the indication doesn't apply: no excess VAT, no metabolic syndrome, no NAFLD, no HIV-associated lipodystrophy, peak natural GH baseline. Adding exogenous GH stimulation at 20 carries glucose-intolerance risk (HbA1c increase signal in trials), edema/carpal-tunnel risk (relevant given Dylan's existing cubital-tunnel concern), and IGF-1 elevation into a range where 47% of trial subjects exceeded +2 SDS at 26 weeks (theoretical cancer-promotion concern over decades). MEDIUM confidence not HIGH because tesamorelin is genuinely the best-validated of the GH-axis peptide family and "skip" doesn't mean "bad drug" — it means "wrong patient." Would change verdict if Dylan reaches 30+ AND develops measurable visceral adiposity (waist >40", elevated VAT on DEXA, NAFLD on imaging) AND brain-priority no longer dominates the optimization stack. The cognitive-function angle (HIV-NCD trial 2024-2025) was negative — VAT reduced but cognition did not improve significantly vs. SOC, removing the only mechanism that would have made this brain-relevant.

Testosterone cypionate is pharmacologically near-identical to enanthate (slightly longer ester, same molecule, same effects); the SKIP-AT-20 logic for any exogenous testosterone applies here too — endogenous T is at lifetime peak, HPG suppression risk is real, fertility impact possible, and zero documented benefit in eugonadal 20yo males. Verdict flips only with documented hypogonadism (total T <300 ng/dL × 2 morning draws + symptoms) — and even then enclomiphene is preferred first-line in young men. Revisit at 35-40+ if natural decline crosses symptomatic threshold.

Endogenous testosterone is at lifetime peak in healthy 20yo males; supraphysiologic intervention disrupts a still-developing HPG axis with documented fertility, mood, and lipid risks. Verdict flips to legitimate TRT only if June 2026 panel documents persistent hypogonadism (total T <300 ng/dL on two morning draws + symptoms).

Program was discontinued by Theranexus in 2022 — no commercial product exists. Even if it returned, narcolepsy Phase 2 missed primary endpoint, modafinil monotherapy already covers Dylan's wake-promoting use case, and adding a class IC antiarrhythmic to a healthy 20yo with no cardiac monitoring infrastructure adds risk without clear consumer benefit. Verdict would shift to WATCH-LIST only if (a) program revives under licensing partner with positive Phase 3, or (b) Dylan develops residual modafinil non-response after 6+ months of optimization.

For Dylan's profile — 20yo MMA athlete, brain-priority, late chronotype (not insomnia), no depression — trazodone is solidly inferior to alternatives he's already locked in or has on the WATCH-LIST. l-tryptophan + magnesium glycinate + l-theanine + apigenin + behavioral chronotherapy (V4 + V5 plan) handle his actual problem (phase-shift, not arousal-driven insomnia). If pharmacological escalation becomes warranted, daridorexant 25 mg is the better tool — preserves architecture cleanly, no priapism risk, no α1 blockade, no QTc concern, no anticholinergic-adjacent residual hangover, no anxiogenic m-CPP metabolite. The only scenarios that would flip this verdict to STRONG-CANDIDATE: (a) Dylan develops MDD requiring an antidepressant where trazodone's sedating profile beats SSRI insomnia, or (b) DORAs become unavailable AND tryptophan/magnesium fail AND z-drug substitution is the only alternative — in which case trazodone is the lesser evil vs zolpidem. Neither scenario is anywhere near current state.

Khavinson family broad skepticism stands for Vesugen specifically — and the case for Vesugen is even thinner than for pinealon. KED has only one mildly-cited co-result in the 5xFAD-M dendritic spine paper (and even there EDR/Pinealon was the stronger arm), the "vascular bioregulator" claim is essentially monograph-only, and Western replication is zero. For a 20yo MMA athlete with brain-priority (#1) and intact vasculature, there is no compelling mechanism-aligned use case. Would only revisit if (a) independent (non-Khavinson) replication of any vascular endpoint published, (b) Dylan develops vascular pathology requiring a peptide-level intervention, or (c) bloodwork (~June 2026) flags endothelial / vascular markers that no first-line option addresses better.

Cleanest amphetamine PK on the market and lower IV/intranasal abuse liability than IR Adderall, but oral abuse profile is similar to dexamphetamine and the brain-development concern at age 20 (PFC dopamine axon misrouting in male adolescent rodents — replicated 2023-2025) applies equally. 12-14hr duration also collides with Dylan's late-chronotype migration (evening anxiety + sleep onset push). Verdict flips to STRONG-CANDIDATE only with formal ADHD or BED diagnosis warranting Rx.

For Dylan (lean 20yo MMA athlete, 6'0-6'1 / 185-190 lb, no obesity, no body-composition problem) — **fully NOT-RELEVANT**. Adipotide is a fat-vasculature-destruction agent designed for severely obese populations; in a lean athlete it would either do nothing (insufficient WAT to ablate) or cause net harm (off-target nephrotoxicity with no benefit). Independent of Dylan-fit, the molecule itself is **SKIP-PERMANENT for almost all profiles** because: (a) ZERO human clinical trial data in 14+ years since the 2011 rhesus monkey publication despite intense media attention — this absence is the data; (b) confirmed dose-dependent renal toxicity in the monkey study (kidney PHB1 off-target); (c) FDA never approved a human IND despite the Arap-Pasqualini lab's prominence; (d) gray-market research-chem versions have no quality control and the molecule is structurally complex (cyclic disulfide + D-amino-acid effector) — high probability of vendor-supplied material being misidentified, degraded, or counterfeit; (e) GLP-1/GIP agonists (semaglutide, tirzepatide, retatrutide) now dominate obesity pharmacotherapy with vastly superior evidence + safety. SKIP-PERMANENT (not SKIP-FOR-NOW) because no plausible future scenario rehabilitates adipotide for Dylan or for any user with reasonable alternatives — the drug is functionally abandoned and dominated. MEDIUM confidence: monkey data is real and the molecular biology is interesting (verdict isn't HIGH-confidence-SKIP because the underlying science is genuine), but the regulatory + commercial trajectory + safety flag combination is unambiguous.

Modafinil is now $0.50-1.50/pill via Indian pharmacy and bypasses the hepatic prodrug step entirely. Adrafinil is strictly worse on every metric (slower onset, 3-4× higher mg, hepatotoxicity signal that withdrew it from the French market in 2011) with no compensating benefit. Verdict would only change if modafinil sourcing globally collapsed AND adrafinil access remained — currently inverted.

For Dylan at 20 — lean MMA athlete with no obesity, no weight-loss indication, no body-composition problem. AOD-9604 was specifically developed for obese adults, failed its pivotal Phase IIb weight-loss trial in that population (n=536, OPTIONS trial 2006), and shows no demonstrated body-composition effect in lean / athletic users at all. Even in obese populations the peptide community's subjective fat-loss reports contrast sharply with the negative phase 2 (failed primary endpoint at 12 and 24 weeks). For lean populations, no clinical trial has ever shown meaningful effect. SKIP-PERMANENT (not SKIP-FOR-NOW) because there is no future biomarker / age threshold that would change verdict for Dylan — he is not the target population now, and aging would not move him into it. What would change verdict: development of clinically significant obesity (unlikely given his profile) AND emergence of head-to-head data showing AOD-9604 superior to GLP-1s / better-evidenced alternatives (also unlikely given the molecule's commercial history). MEDIUM confidence (not HIGH) because (a) the Phase IIb negative result was a 24-week trial with intensive diet + exercise that may have masked modest peptide effects, (b) safety profile is genuinely clean across ~900 trial subjects, (c) intra-articular cartilage-repair signal is interesting (Kwon & Park 2015 rabbit data) but irrelevant to Dylan's elbow thread (BPC-157 + TB-500 are far better-evidenced for his use case).

Chronic daily use is contraindicated for every Dylan-relevant goal (cognition, brain preservation, MMA reaction time, sleep architecture, longevity) — the A-tier evidence for tolerance, dependence, severe and sometimes life-threatening withdrawal (seizures, delirium), persistent cognitive impairment, fall/MVA risk, opioid-overdose synergy, and protracted withdrawal syndrome (BIND, 6–18+ months) all converge on chronic-use-bad. Acute single-dose / true emergency PRN use under a prescriber (status epilepticus, pre-procedural anxiolysis, one-off catastrophic panic) is medically appropriate and not what this verdict targets — but for a 20yo nootropic-stack user with no diagnosed anxiety disorder, no seizure history, and a brain-priority goal set, this class is a permanent skip. Nothing about chronic recreational/cognitive/sleep use would change this verdict; the verdict is class-wide because the abuse, dependence, withdrawal, and cognitive-impairment hazards are mechanistically pan-class even though potency, half-life, and subjective profile vary by molecule.

For Dylan and essentially every non-clinical user, Desoxyn sits one full tier above Adderall/Dexedrine on tolerance/abuse/neurotoxicity trajectory with no compensating cognitive advantage that survives the cost-benefit. It is FDA-approved (ADHD + obesity) and pharmaceutically real, but in modern US practice essentially never prescribed — the prescriber DEA exposure, the cost, and the clean availability of Vyvanse/Adderall make it a non-starter clinically. Even granting clinical legitimacy, the brain-development concern at 20 + dopaminergic terminal toxicity signal + appetite suppression severity + faster abuse trajectory all point the same direction. Verdict would not flip even with an ADHD diagnosis — Vyvanse or Adderall would be the appropriate first-line.

Hepatotoxicity is among the worst of any oral AAS, the aggression-promoting profile actively conflicts with brain priorities, and zero brain or longevity upside justifies the liver/CV/neurobehavioral risk — no plausible bloodwork or genetic finding flips this verdict.

Decades of pharmacology show oral GABA does not cross the BBB at meaningful concentrations, and the proposed alternative pathway (ENS → vagus → CNS) — while real and now reasonably well-characterized in 2024-2025 microbiota literature — is mechanistically weaker than every other tool already in Dylan's stack for the same goal. L-theanine, magnesium glycinate, glycine, taurine, tryptophan, and (PRN) picamilon all do the "calm" job either through actual BBB-crossing molecules or through better-evidenced peripheral mechanisms. There is no Dylan-relevant niche where oral GABA is the right tool. Verdict would change only if a Western-grade RCT demonstrated unambiguous central GABA-A engagement after oral dosing (MR-spectroscopy brain GABA increase + matched subjective effect), which would invalidate ~60 years of BBB pharmacology — extraordinarily unlikely. Picamilon already covers the "BBB-crossing GABA prodrug" niche.

For nootropic / cognitive-enhancement use in Dylan, gabapentin is structurally wrong (the name implies GABAergic anxiolysis it cannot deliver), produces dose-dependent cognitive blunting (attention, processing speed, working memory in healthy crossover RCTs), carries a real and increasingly-recognized 2018+ dependence/abuse signal (15-22% misuse prevalence in opioid-using populations, 1% general population, ~5,000 US deaths/year involving gabapentin since 2020), and offers zero cognitive enhancement. The legitimate indications (post-herpetic neuralgia, diabetic peripheral neuropathy, focal epilepsy adjunct, restless legs, alcohol withdrawal taper) are all medical Rx contexts that don't apply to him. Verdict would only flip to OPTIONAL if Dylan develops a documented neuropathic pain syndrome (e.g., the cubital tunnel ulnar neuropathy progresses to chronic neuropathic pain unresponsive to peripheral interventions and BPC-157/TB-500 protocol), at which point it becomes a tool for that specific medical problem, not a cognitive enhancer. Nothing about cognitive-enhancement framing changes the verdict.

GHB has the narrowest therapeutic window of any commonly-encountered psychoactive — recreational-to-unconscious gap is roughly 1.5-3 g vs 3-5 g (literally one extra "capful" of GBL or one mis-measured shot), and recreational-to-respiratory-arrest is 5-15× the active dose. Mixed with alcohol (multiplicative respiratory depression, no specific reversal agent), it is one of the highest case-fatality-rate club drugs in Western Europe (10.6% of acute drug toxicity presentations + 27% of critical-care admissions in Euro-DEN 2019 hospitals). Withdrawal from chronic use is among the most severe in clinical addiction medicine — fulminant autonomic crisis + delirium in >50% of untreated cases, ICU admission ~20-31% in observational cohorts, benzodiazepine-resistant in many cases (different receptor target — GHB acts at GHBR + GABA-B, BZDs at GABA-A), often requiring pharmaceutical GHB re-administration to abort. Sodium oxybate (Xyrem/Xywav/Lumryz) under REMS supervision IS A-tier evidence for narcolepsy/cataplexy/idiopathic-hypersomnia — but the safety envelope depends on the REMS architecture (single dispensing pharmacy, dose titration, monitoring, prohibition of alcohol/CNS-depressants, $177-212K/yr), none of which transfer to biohacker self-dosing. SKIP-PERMANENT applies to ALL non-narcoleptic archetypes; OPTIONAL only for diagnosed narcolepsy/cataplexy/IH under REMS. Verdict would change only if (a) a non-tolerizing GHB analog were discovered, or (b) Dylan develops narcolepsy with cataplexy and exhausts non-oxybate options — neither plausible.

Imuracetam (developmental code UCB-G218) is a UCB Pharma 1970s-era racetam candidate that was never marketed and has no published human clinical trials, no commercial form, no available reference standard for research-chem synthesis, and no community sourcing pathway. PubMed returns zero direct results (only auto-correction to the unrelated compound dimiracetam). It is effectively vaporware in the user/biohacker sense — there is no actionable compound to source, dose, or stack. The user should consult the documented, available racetams instead (piracetam, aniracetam, oxiracetam, phenylpiracetam, etc.).

Among oral anabolics methyltestosterone is strictly dominated — it has the worst hepatotoxicity profile of any clinically used 17αAA, weaker anabolic effect than oxandrolone/oxymetholone/methandrostenolone, and aromatizes to a methylestradiol that is itself harder for the liver to clear. Anyone wanting oral androgen has better tools (oxandrolone for mild, methandrostenolone for mass with cycled liver hits); anyone wanting testosterone has injectable T-enanthate/cypionate at 1/100th the hepatic load. Verdict would only change if a novel hepatoprotective derivative emerged — currently none exists.

Methyltrienolone stacks 17α-methyl hepatotoxicity (worst-class oral) on top of trenbolone-class psychiatric/CV/HPG damage — it sits in the "essentially universally bad idea" tier of AAS, with no human-medical use case in 60+ years and no plausible bloodwork or genetics result that could flip this for any user, let alone a 20yo brain-priority MMA athlete.

Off-label bodybuilding use carries acute lethal hypoglycemia risk for any non-diabetic. Dylan is 20, lean, insulin-sensitive, untested AAS-naive — there is no scenario where exogenous insulin makes sense. Would change only if Dylan develops type 1 diabetes (medically necessary) — which is unrelated to biohacker use.

Phenibut produces severe physiological dependence within 1-3 weeks of regular use, withdrawal that mirrors benzodiazepine/alcohol withdrawal severity (autonomic crisis, delirium, seizures, ICU-level care), and a 2024 systematic review documenting 44% of withdrawal cases requiring ICU, 24% intubated, 8% with seizures. Recreational doses (1-3 g) used in biohacker contexts are 5-15× the Russian therapeutic dose (250-500 mg). The dependence pharmacology is fundamental to the molecule — there is no safe low-dose intermittent protocol that survives contact with weekly use. For an anxiolytic effect, Selank (zero-dependence) and L-theanine + taurine (free-tier) cover the use case without the abyss. Verdict applies to ALL archetypes — no compelling clinical use case where benefit exceeds dependence risk for a non-prescribed user. Would change ONLY if a non-tolerizing analogue of phenibut were discovered or if molecular-tolerance data fundamentally re-wrote the dependence model — neither is plausible given 60+ years of clinical data. Dylan-specific reinforcement: at 20 with high cognitive workload + MMA training + zero substance baseline, introducing a known dependence trap is a strict downside trade.

Genuine A-tier efficacy for neuropathic pain, fibromyalgia, and GAD — but Schedule V scheduling, rapid tolerance, severe withdrawal, weight gain, sedation, and a real abuse signal make it strictly worse than the alternatives Dylan already has access to (L-theanine, propranolol PRN, magnesium, sleep optimization). For nootropic use, no scenario flips this. For specific Rx indications (post-injury neuropathic pain, intractable GAD that fails SSRIs/buspirone) — OPTIONAL under physician supervision only.

For Dylan specifically — at 6'0-6'1, 185-190 lb, ~10+ hr/wk MMA training, brain-priority — retatrutide is medically wrong-fit, not bad. Strong appetite suppression + glucagon-driven energy redirection actively undermines the protein/calorie surplus and cardiovascular workload his sport demands; lean-mass loss risk with class drugs is well-documented; cognitive priority is unaffected. Verdict is HIGH-confidence SKIP-PERMANENT for HIM. The drug itself is best-in-class for obesity / metabolic syndrome — verdict for that population is STRONG-CANDIDATE pending FDA approval. File entry exists for wiki completeness, not for Dylan's stack.

UCB Pharma discontinued seletracetam development circa 2008-2009 in favor of brivaracetam, which advanced to FDA approval (2016). Seletracetam never reached Phase 3, has zero post-2009 publications, no human nootropic data, and no commercial or gray-market sourcing path. The molecule is functionally vaporware. Verdict will not change unless UCB or a successor sponsor revives the asset (no signal of this in 16 years). For any SV2A-based use case, brivaracetam is the only viable option — and even that has minimal nootropic evidence in healthy adults.

Dylan is 20 with peak BMD intact and no osteoporosis indication; teriparatide is a fracture-prevention drug for severe low BMD populations and offers nothing for a young athlete. Would change only if a serious fracture-prone osteoporotic state emerged decades from now.

Functionally an opioid antidepressant masquerading as a "nootropic" — at biohacker doses (250-4000+ mg/day vs 37.5 mg therapeutic) it is opioid-class abuse with full dependence, withdrawal, respiratory depression, and death; non-opioid alternatives exist for every plausible use case. Nothing realistic would change this.

Stacked HIGH-risk profile (brain-development + psychiatric + cardiovascular + HPG) for a 20yo athlete with brain as #1 priority makes Tren a categorical no — there is no plausible future blood/genetics result that flips this verdict.

Tren E is trenbolone's pharmacology with a longer ester — same brain/CV/HPG damage profile as parent trenbolone, with worse "stuck-with-side-effects" risk because the long ester takes weeks to clear if the user wants to abort. For a 20yo brain-priority MMA athlete the compound is categorically wrong; the long ester actively makes it worse than the acetate version.

Severe HPG-axis shutdown in a developing 20yo endocrine system + WADA-banned + gray-market only + zero brain-priority benefit + Population Council designed it specifically AS a male contraceptive (the suppression is the desired clinical effect). No pathway to "yes" for Dylan.

For chronic use the pharmacology is fundamentally suboptimal — they impose GABAergic sedation on the brain rather than removing wake drive, suppress N3/REM architecture in some studies, carry a 2019 FDA Boxed Warning for fatal complex sleep behaviors (sleep driving, sleep eating, sleep cooking, ingestion of unsafe substances), produce anterograde amnesia, build tolerance + dependence + rebound insomnia within weeks, and a 2021 case-control study found 79% greater dementia risk in older adults using Z-hypnotics >28 days per quarter. Daridorexant and seltorexant achieve sleep without GABAergic sedation, preserve sleep architecture, have no rebound or dependence through 12 months, and preserve next-day cognition. There is no reason for a brain-priority 20-year-old to ever touch this class chronically. OPTIONAL only for very acute, prescriber-supervised, short-course (≤2 weeks) insomnia where DORAs are unavailable. Verdict will not change — pharmacology is the problem.

Documented for completeness alongside teriparatide.md. Abaloparatide is a fracture-prevention drug for severe postmenopausal osteoporosis; Dylan is 20 with peak BMD and no osteoporosis indication. Not relevant. Verdict would only change in a remote future scenario of severe low BMD.

Anastrozole exists for one class of problem — pathologically elevated estradiol — across four indication clusters (HR+ breast cancer, AAS-induced E2 elevation, TRT E2 management, idiopathic precocious puberty / pubertal gynecomastia). Dylan at 20 has none of these. He has an intact HPG axis, no anabolic steroid use, no exogenous testosterone, no breast cancer, and no documented gynecomastia. There is zero indication for an aromatase inhibitor, and crashing E2 in a young eugonadal male is actively harmful — low E2 in men produces joint pain, libido collapse, lipid disruption, mood blunting, and accelerated bone loss within months. Verdict shifts to WATCH-LIST only if June 2026 bloodwork shows symptomatic E2 >50 pg/mL with an identifiable cause; shifts to STRONG-CANDIDATE only in the contingency that he initiates TRT or AAS use (not on roadmap) and develops symptomatic high-E2 phenotype.

For Dylan at 6'0-6'1 / 185-190 lb / 10+ hr/wk MMA / no metabolic disease, bioglutide has zero indication. Even with the "muscle-sparing" advantage being real (Phase 2 clinical signal with 0% lean loss vs. class-typical 25-40%), the drug remains an aggressive multi-receptor metabolic intervention designed for obesity and T2D — populations Dylan is not in. The IGF-1R activation arm (the differentiating feature) creates additional uncertainty for an athlete with normal endogenous IGF-1, including theoretical concerns about supraphysiological IGF-1 signaling, off-target growth effects, and unclear long-term cancer risk profile (IGF-1 axis is implicated in oncogenesis at sustained high levels). For a young lean athlete with no metabolic indication, this profile is downside-only — caloric deficit + appetite suppression + glucagon-driven energy depletion oppose MMA fueling and cardio capacity, while the supposed "upside" of IGF-1R activation creates additional unknown risk vector. Investigational status (Phase 2b/3, no FDA approval, gray-market sourcing only) compounds the no-go. Verdict only re-opens with substantial physiology change AND post-approval safety data at multi-year horizons.

Surgical-only osteoinductive protein. Dylan has no fracture, no spinal pathology, no bone defect. Cancer signal in surgical literature reinforces avoid for non-indicated use. Would change only if a documented non-union fracture occurred.

Brivaracetam is a third-generation anticonvulsant designed exclusively for partial-onset (focal) seizures in patients with epilepsy. Dylan has no seizure diagnosis, no documented epileptiform EEG findings, no head injury severe enough to require seizure prophylaxis, and no other indication for SV2A modulation. The healthy-adult cognitive-enhancement evidence base for brivaracetam is **literally zero** — no published trials, no n>1 case reports, no meaningful subjective dose reports. Levetiracetam (the parent compound) has equally thin nootropic data and a worse psychiatric AE profile, and brivaracetam was not designed to improve on that gap — it was designed to keep epilepsy efficacy while reducing psychiatric AEs. Sourcing is also a real friction: brivaracetam is still mostly under brand-protected pricing in the US (~$300+/month cash) with limited Indian generic availability emerging in 2024-2025. Verdict shifts to NOT-RELEVANT-but-flagged only if a bona fide post-traumatic seizure indication arises (e.g., a serious MMA head injury producing focal seizures), at which point it becomes a medical Rx decision with neurology, not a self-curated nootropic tool. The HIGH confidence here is dual-tracked: LOW confidence that brivaracetam does anything cognitively interesting in healthy adults (no data either way), HIGH confidence that "this isn't a nootropic" — the molecule's design brief, evidence base, and clinical positioning all point in the opposite direction from cognitive enhancement.

For Dylan specifically — at 6'0-6'1, 185-190 lb, no metabolic disease, no obesity, no T2DM, active MMA career — there is no indication for amylin agonism. Mechanism is appetite suppression + delayed gastric emptying + ~22% weight loss in combination, all of which directly oppose MMA fueling and lean-mass preservation needs. Not yet FDA-approved standalone (CagriSema submission pending). MEDIUM-HIGH (not HIGH) confidence because Phase 3 evidence is mature and well-replicated but the drug isn't approved yet — verdict is on mechanism + indication mismatch, which is robust regardless of approval timing. Distinct from semaglutide's SKIP-FOR-NOW because cagrilintide won't be available standalone; relevant population question is "would CagriSema be relevant if Dylan ever had obesity + T2DM?" — answer: STRONG-CANDIDATE for that population, NOT-RELEVANT for current Dylan. File entry exists for wiki completeness, not for Dylan's stack.

For Dylan (20yo MMA athlete, no cardiac pathology, intact myocardium): the entire claimed use case — cardiac tissue support, post-MI recovery, age-related cardiomyopathy adjunct — does not exist in this profile. Khavinson family broad skepticism applies (zero Western replication, single-source evidence, contested mechanism). Even if every Khavinson claim were true, Cardiogen would have nothing to act on in a 20-year-old healthy athlete's heart. NOT-RELEVANT (rather than SKIP-FOR-NOW) reflects that this isn't a "weigh evidence vs. risk" question — it's a "no indication exists" question. Confidence is LOW because the underlying compound's evidence base is itself low-confidence; we're certain it's irrelevant for Dylan, less certain it does anything for anyone.

Daytrana is a niche pediatric ADHD delivery system whose entire value proposition is solving problems Dylan does not have — kids who can't swallow pills, kids who hide pills, families needing flexible afternoon-cutoff control. For a 20yo MMA athlete, the patch is **mechanically defeated by Dylan's daily reality**: BJJ sparring tears patches off, prolonged sweating disrupts adhesion and flux, and skin contact during grappling rubs the patch onto a training partner (a Schedule II transfer event). Add the >30% incidence of application-site erythema, the 2015 FDA warning on **chemical leukoderma (permanent skin lightening)**, and ~$400-600/month retail cost for what is functionally Ritalin in a less convenient package — there is no scenario in which Daytrana beats every oral methylphenidate option. Verdict would shift only if (a) Dylan stopped grappling AND (b) developed an oral methylphenidate-class indication AND (c) had specific issues with oral delivery (rare swallowing problem, severe GI absorption issue) — none plausible.

No indication for Dylan. Better-tolerated than venlafaxine but similar emotional/sexual side effects. Pain dual-indication (DPN, fibromyalgia, chronic LBP) is unique value but Dylan has no pain syndrome.

Dylan is 20yo with no HF, no post-MI history, no resistant HTN, and no primary aldosteronism — eplerenone has no current indication. The single niche where it could plausibly become relevant is topical eplerenone for male-pattern baldness if minoxidil monotherapy fails and he wants to avoid oral 5α-reductase inhibitors; that is WATCH-LIST experimental with weak evidence, not standard care. Verdict would shift to STRONG-CANDIDATE only on a heart-failure or post-MI diagnosis (vanishingly unlikely at 20), or to OPTIONAL-ADD as on-cycle water-retention control if he ever runs AAS. Documented here for completeness and the MPB-topical exploratory question.

Cleanest SSRI profile (least drug interactions, fewest off-target effects) but still NOT-RELEVANT for Dylan absent clinical anxiety/depression. First-line if SSRI ever indicated.

Ezetimibe is a clean, well-tolerated, A-tier evidence-base lipid-lowering drug with proven CV outcome benefit (IMPROVE-IT 2015, RACING 2022). At 20yo with no known dyslipidemia and no bloodwork yet, it is NOT-RELEVANT. Verdict would upgrade to STRONG-CANDIDATE if June 2026 bloodwork shows ApoB >100 mg/dL or LDL-C >130 mg/dL with a "lean reactor" / hyperabsorber phenotype, or to PRIMARY-PICK if FH (familial hypercholesterolemia) is detected via 23andMe or pedigree. Verdict would stay NOT-RELEVANT if lipids are normal.

Designed for overweight/obese populations needing modest fat-loss support alongside diet/exercise; Dylan is a lean MMA athlete with no fat-loss goal, no B-vitamin deficiency, and no liver dysfunction. Would only become relevant on bulk-cut cycle if he ever entered an obesity-band BMI — vanishingly unlikely.

Disease-specific therapy for achondroplasia/skeletal dysplasia driven by FGFR3 G380R gain-of-function mutation. Dylan has normal stature (6'0-6'1) and no FGFR3 pathology. Would change only if a pediatric/adolescent FGFR3-mutation patient needed it (not Dylan).

No clinical indication for Dylan. Longest half-life of SSRI class (less withdrawal but slower clearance) doesn't change the basic mismatch — emotional blunting + sexual dysfunction not justified absent diagnosis.

Sparse Russian-only data + unreliable gray-market sourcing + Selank already covers Dylan's anxiolytic role with a multi-mechanism profile and a 17-year clinical track record. GB-115 is mechanistically interesting (CCK-B antagonism is the panic-disorder axis) but offers Dylan no incremental benefit over what Selank delivers. Verdict would upgrade to WATCH-LIST if (a) Western RCT data emerged, (b) Dylan develops panic-disorder-flavored anxiety that Selank's GABA/enkephalinase axis fails to address, or (c) sourcing stabilizes with verified COA.

hCG is a Leydig-cell stimulator used in three clinical contexts — TRT testicular preservation, post-AAS PCT, and male infertility. Dylan has none of these conditions: no AAS use, no TRT, intact HPG axis at peak natural function, no fertility concerns. Compound is documented for completeness; no scenario in 2026 makes it relevant absent a major change in clinical status. The "hCG diet" (Simeons protocol) is empirically debunked — multiple placebo-controlled trials show weight loss tracks caloric restriction, not hCG.

HCTZ is a first-line antihypertensive — useful for documented hypertension, mild heart failure, kidney stones. Dylan has no hypertension, no heart failure, normal renal function. Bodybuilding "cutting" use carries severe electrolyte risks. Would change only if Dylan develops sustained HTN (unlikely at 20).

At 20yo with intact HPG axis, applying upstream stimulus to a system already running at peak natural output is an intervention without an indication. Verdict re-evaluates only in three specific scenarios: (a) post-AAS-cycle restart adjunct (currently N/A — Dylan is not on AAS, would not be at 20), (b) documented infertility / hypogonadotropic hypogonadism on workup (biologically unlikely at 20), or (c) clinical trial enrollment at Imperial College / Dhillo lab equivalent. Verdict has MEDIUM rather than HIGH confidence because the post-AAS-PCT use case is real and well-discussed in peptide community even though it is currently irrelevant to Dylan's protocol.

Anticonvulsant with no healthy-adult cognitive-enhancement signal — most of the cognitive literature in healthy subjects shows neutral-to-blunting effects on attention, processing speed, and verbal fluency, plus a real ~10-20% rate of "Keppra rage" psychiatric AEs (irritability, anxiety, depression, suicidality) that disqualifies it as a daily nootropic for a 20yo with no seizure indication. The Bakker 2012 / Vossel 2021 LIFT-AD low-dose (125 mg BID) hippocampal-hyperactivity-suppression line is genuinely interesting for amyloid-positive MCI/early-AD older adults and lands the compound on the WATCH-LIST for that archetype — but it does not generalize to healthy young brains, where there is no hippocampal hyperactivity to suppress and the AE profile is the only thing left. Verdict would change only if (a) Dylan develops a seizure indication (becomes a clinical Rx decision, not a nootropic decision), or (b) Dylan ages into amyloid-positive MCI status and a future LIFT-AD-style trial replicates with hard endpoints, at which point the WATCH-LIST → consideration pathway opens for older-Dylan, not 20-year-old Dylan.

Component evidence is decent (each ingredient has independent literature); zero RCTs of the actual Lipo-C blend for weight loss; oral bioavailability of all components is sufficient at supplementation doses; Dylan is a 20yo lean MMA athlete with no fat-loss target, no liver disease, no choline deficiency, eats whole-food diet, and already has B-complex/choline coverage in V4 stack. Verdict would change to OPTIONAL placebo+ only for the older obese / metabolic-syndrome user where motivation and clinic-engagement value compete with negligible direct biochemical benefit.

LL-37 is a high-leverage tool when you have a chronic infection, biofilm-driven indication, mold-biotoxin (CIRS) pattern, refractory chronic rhinosinusitis, or chronic Lyme — none of which Dylan has. The peptide is the "L" in the KLOW combat-recovery stack (KPV + LL-37 + GHK-Cu + BPC-157 + TB-500), but for Dylan the antimicrobial slot in that stack is unjustified — his V4 stack is targeted at cognitive/recovery/sleep/skin-irritation issues without an underlying infection driver. Confidence MEDIUM (not HIGH on the SKIP) because (a) there's a theoretical "broad-spectrum prophylaxis" rationale during heavy training blocks where mucosal immunity gets stressed, (b) Dylan's perioral dermatitis MIGHT have a low-grade staph or Demodex colonization component for which LL-37 topical could matter, and (c) the dual-nature immunomodulation makes this peptide one of the most context-dependent in the catalog — wrong context = wrong outcome. Verdict for Dylan stays NOT-RELEVANT because he has no chronic infection indication and his existing V4 + planned BPC-157 protocol covers his actual problems. Would upgrade to OPTIONAL if (a) chronic refractory sinus infection emerges, (b) recurrent skin infections from mat exposure (impetigo, folliculitis, MRSA colonization) become a clinical issue, or (c) bloodwork in June 2026 shows mold-biotoxin / CIRS markers (C4a, TGF-β1, MMP-9 elevated). Would upgrade to STRONG-CANDIDATE only with diagnosed chronic Lyme, CIRS, or biofilm infection.

For Dylan specifically — at 6'0-6'1, 185-190 lb, 10+ hr/wk MMA training, no metabolic indication — mazdutide is medically wrong-fit, not bad. No indication exists; appetite suppression undermines training fueling; glucagon-driven catabolic + thermogenic skew opposes anabolic recovery in a way that is even more pronounced than tirzepatide's GIP-arm profile; lean-mass-loss class issue applies; no cognitive upside; not US-approved so sourcing would be gray-market for a drug he doesn't need. Verdict for Dylan is HIGH-confidence NOT-RELEVANT and is robust to any plausible new data given his current physiology. The drug itself is best-in-Chinese-evidence for obesity + T2D — verdict for that population (when approval lands) is STRONG-CANDIDATE. File entry exists for wiki completeness.

Mechanism is plausible but the entire human evidence base is Russian-only — Voronina / Seredenin / Zakusov Institute lineage — with no Western RCTs, no Western case series, no English-language pharmacology beyond translated abstracts. For Dylan-archetype the compound would be mechanism-redundant on top of Semax + Adamax + Bromantane (planned) + modafinil + the V4 base; sourcing is harder than noopept (less common at RUPharma/CosmicNootropic), data is sparser than noopept, and the marginal contribution is unclear. Verdict would upgrade to WATCH-LIST only if (i) a Russian-language literature dive surfaces meaningful signal beyond the Zakusov ecosystem, or (ii) Adamax/Semax/Bromantane fail to deliver and a different glutamate-axis compound is wanted that noopept cannot fill.

For Dylan at 6'0-6'1 / 185-190 lb / 10+ hr/wk MMA / no metabolic disease, orforglipron has zero indication. Class-typical GLP-1 effects (appetite suppression, ~25-40% lean-mass-loss fraction, GI burden) directly oppose MMA fueling, recovery, and protein needs; no cognitive upside; no CV/renal/OSA indication exists. Distinct verdict from semaglutide's SKIP-FOR-NOW because orforglipron is even less weight-effective at top dose (~11% vs. semaglutide's ~15% vs. tirzepatide's ~20%) — there's no scenario where orforglipron beats the existing class for a non-Dylan profile that ALSO applies to him. Wiki-completeness entry. The drug's distinctive feature — needle-free oral dosing — is exactly the feature that doesn't matter for Dylan since he has no indication regardless of administration route.

Interesting bench-science peptide for bone formation + hematopoiesis but human clinical data is essentially zero. Dylan has no bone deficit, no marrow suppression, no fracture. Would change only if a small clinical trial showed safety + efficacy AND Dylan had a bone indication.

Real, mechanistically distinctive anticancer peptide with ~25 years of preclinical work and a clean selectivity story (membrane HDM-2 expressed only on cancer cells). But ZERO verified human clinical trials, FDA warning citing bacterial contamination in marketed product, and Dylan has no cancer indication. Not a candidate compound — listed only for encyclopedic completeness and so the cancer-adjunct case is properly framed if it ever becomes relevant. WATCH-LIST experimental ONLY under oncologist supervision for someone with active malignancy.

Prostate-tissue bioregulator with no use case in a 20yo MMA athlete with intact urogenital function. Khavinson family broad skepticism stands. Prostamax has zero Western RCTs, single-source Russian preclinical data, and no profile-aligned indication for Dylan. Verdict reflects "not in scope at all" rather than active rejection of the compound for someone with a prostate indication.

Dylan is a 20yo MMA athlete with peak HPG-axis function, no reported sexual dysfunction, no HSDD-equivalent indication, no PDE5-non-responsive ED, no low libido complaint. PT-141 is FDA-approved for premenopausal women with HSDD and used off-label by men with vascular-non-responsive ED — neither maps onto Dylan's profile at any dose. Documented in this wiki for completeness as the FDA-approved cleaner cousin of MTII (which is itself SKIP for Dylan). Verdict shifts to OPTIONAL-PRN only if Dylan develops PDE5-non-responsive ED, situational psychogenic erectile difficulty, or specific sexual function complaint at any future age. Verdict shifts to STRONG-CANDIDATE in the alternate universe where Dylan is a postmenopausal woman with HSDD or a 50+ male with vascular ED unresponsive to sildenafil/tadalafil. None of these apply.

Quillivant XR is an FDA-approved liquid suspension formulation of extended-release methylphenidate designed for **pediatric patients (ages 6-17) who cannot swallow pills** — dysphagia, autism with oral aversion, very young children, feeding tubes. Pharmacokinetically near-equivalent to Concerta XR (12-hour duration, ascending plasma curve, same active drug) but at **5-10x the cost** (~$300-450/month brand-only retail vs. $30-60/month for generic Concerta) with **zero adult use case advantage**. For Dylan (20yo, can swallow, no ADHD diagnosis, methylphenidate-class already SKIP-FOR-NOW due to chronotype + lane already owned by modafinil), Quillivant offers no benefit any other methylphenidate formulation doesn't — it is strictly a niche pediatric product. Verdict would change only if Dylan developed dysphagia or feeding-tube dependence AND had clinical ADHD diagnosis AND could not access cheaper liquid alternatives like Methylin oral solution (IR, BID) or compounded MPH suspensions.

Raloxifene's three indication clusters (postmenopausal osteoporosis, breast cancer chemoprevention in postmenopausal women, male AAS-induced/pubertal gynecomastia, and schizophrenia adjunct in postmenopausal women) all require a phenotype Dylan does not have. He is a 20yo male with no anabolic steroid exposure, no documented gynecomastia, no schizophrenia, and intact endogenous testosterone production. There is no conceivable indication for raloxifene in his current profile, and the VTE/DVT/PE risk + libido suppression in eugonadal men make off-label exploration actively harmful. Verdict shifts to STRONG-CANDIDATE only if he develops moderate-severe gynecomastia from any cause (idiopathic, AAS use he doesn't currently do, or rare prolactinoma) and tamoxifen is contraindicated — a multi-step contingency that is essentially zero probability.

No psychiatric indication for Dylan; SSRI for healthy adults reduces anabolic drive, blunts emotion, often impairs sexual function. Would change if Dylan developed clinical anxiety/depression unresponsive to behavioral interventions.

Mechanism is real (SNARE-competitive inhibition is well-characterized in vitro), but topical penetration to neuromuscular junctions is the bottleneck — clinical effect is ~10-20% of injectable Botox and only on dynamic (movement-induced) fine lines, not static wrinkles or deep folds. For Dylan (20yo, no wrinkles, no cosmetic-aging indication): NOT-RELEVANT — there is nothing to treat. For 35+ users with starting-to-form expression lines, it's a low-risk, low-cost cosmetic add-on with modest evidence. Verdict would change for Dylan only if he develops bothersome forehead/eye lines (decade+ from now) or if a delivery-vehicle innovation closes the penetration gap to make topical SNARE-inhibitors actually competitive with injectable BoNT.

For Dylan specifically — at 6'0-6'1, 185-190 lb, 10+ hr/wk MMA training, no metabolic indication — survodutide is medically wrong-fit, not bad. Strong appetite suppression directly opposes MMA fueling needs; class-typical lean-mass loss + glucagon-driven catabolic skew opposes muscle preservation; no cognitive upside; no indication exists; investigational status means no Rx pathway anyway. Verdict robust. The drug itself is STRONG-CANDIDATE (when approved) for severe obesity + MASH given Phase 2 results (~19% weight loss at 4.8 mg / 46 wk; 62% MASH resolution at 4.8 mg). File entry exists for wiki completeness, not for Dylan's stack.

Dylan has no documented thyroid dysfunction; T3 in a euthyroid 20yo is a CV-strain compound with no upside. Revisit only if June 2026 bloodwork shows hypothyroidism (TSH high, fT4/fT3 low) — then OPTIONAL-ADD under endocrinologist.

Dylan is 20yo male with intact HPG axis at peak natural function, no AAS exposure, no documented or symptomatic gynecomastia, no breast cancer / no BRCA mutation, no fertility concern requiring SERM-driven HPG amplification. There is no indication for tamoxifen in his current profile. Off-label exploration would impose endometrial-irrelevant-but-VTE-real risk, libido suppression, vision risk, and CYP2D6-genotype-dependent unpredictable exposure — with zero compensating benefit. Verdict shifts to STRONG-CANDIDATE only if he develops AAS-induced or severe idiopathic gynecomastia, or pursues an AAS cycle requiring PCT (not on roadmap). Documented here for AAS/PCT context and because users searching "SERM" reach this file.

Dylan is 20yo with no hypertension and no current AAS use; an antihypertensive ARB has no primary indication and the PPARγ insulin-sensitization edge is too weak to justify a daily Rx in someone with already-good metabolic markers. Verdict would change to STRONG-CANDIDATE the moment he runs an AAS cycle (telmisartan is the preferred ARB for cycle BP control), develops HTN (>130/85 sustained), or shows worsening insulin/lipid markers in bloodwork. Documented here for those future contexts, not for current use.

Khavinson family broad skepticism stands. Testagen specifically is pitched as an endocrine bioregulator, with the most concrete mechanism story being TSH→thyroid→testosterone (a 3-link inferential chain) plus monograph-only direct testicular claims. Dylan is 20yo with an intact HPG axis, no clinical hypothyroidism, no documented low-T — there is no profile-aligned use case. Verdict would only flip if (a) bloodwork (~June 2026) flags low-normal T or sub-clinical hypothyroidism that no first-line option addresses better, (b) independent (non-Khavinson) replication of any pituitary or testicular endpoint published, or (c) Dylan ever runs an AAS cycle and wants experimental post-cycle adjuncts (in which case enclomiphene / hCG dominate on evidence).

For Dylan specifically — at 6'0-6'1, 185-190 lb, 10+ hr/wk MMA training, no metabolic indication — tirzepatide is medically wrong-fit, not bad. Strong appetite suppression directly counters MMA fueling needs; class-average ~25-40% lean-mass-loss fraction is incompatible with combat sport requiring muscle preservation; no cognitive upside; no indication exists. Distinct from semaglutide's SKIP-FOR-NOW because tirzepatide is even more potent (superior in head-to-head SURMOUNT-5), making lean-mass risk arithmetically larger per kg lost. The drug itself is best-in-class for T2D + obesity and now leads on OSA — verdict for those populations is STRONG-CANDIDATE. File entry exists for wiki completeness, not for Dylan's stack.

No indication for Dylan. Notorious withdrawal syndrome (worst of the SNRIs). Effective drug for severe MDD/GAD but high discontinuation burden + side-effect profile not justified absent diagnosis.

NOT-RELEVANT for Dylan with MEDIUM confidence (not HIGH) because: (a) Dylan has no CIRS, no autoimmune disease, no pulmonary HTN, no chronic inflammation pattern — the indications where VIP has even B-tier evidence are absent; (b) VIP is mechanism-rich but its evidence base is concentrated in disease-state correction (CIRS, autoimmune flare reduction, pulmonary failure rescue), not healthy-baseline enhancement — there is no defensible benefit for a healthy young athlete; (c) the cost ($300-500/month compounded intranasal) is high relative to no expected benefit; (d) the CIRS Shoemaker protocol is itself controversial within mainstream medicine (see Controversies section). Confidence is MEDIUM rather than HIGH because (i) VIP's circadian-SCN role is genuinely mechanistic-interesting and a hypothetical case for sleep/circadian use in healthy populations exists in theory but has no human RCT support; (ii) intranasal CNS delivery means VIP is one of relatively few peptides with credible brain-penetration mechanism, which keeps it on the watch list for future indications; (iii) Aviptadil's COVID-ARDS Phase 2b/3 data (Youssef 2022) is genuinely positive for the mechanically ventilated subgroup, validating that VIP is bioactive in humans even if irrelevant for Dylan. Verdict would shift to WATCH-LIST or OPTIONAL-ADD only if Dylan develops (a) confirmed CIRS from biotoxin / mold exposure following Shoemaker's full diagnostic protocol; (b) chronic autoimmune diagnosis with refractory inflammation; (c) chronic pulmonary disease; or (d) is in a position to participate in research-grade circadian-disorder protocol. Verdict would NOT shift on the basis of "general immune support" or "anti-inflammatory" claims — those are mechanism-extrapolation without healthy-user evidence.

"Agmatine sulfate" is the standard salt form sold as a supplement — virtually all commercial agmatine is the sulfate salt. The pharmacology, dosing, evidence, and Dylan verdict are identical to the parent agmatine.md entry. This file exists as a name-search stub.

"Citicoline" and "CDP-choline" are the same molecule under two naming conventions (citicoline = INN/USAN; CDP-choline = chemistry literature). The pharmacology, dosing, evidence, and Dylan verdict (CONFIRMED-IN-USE in V4) are identical. This file exists as a name-search stub for users who know the compound by either name.

"Elvanse" is the EU/UK trade name for the same molecule sold in the US/CA/AU as Vyvanse — both are lisdexamfetamine dimesylate manufactured by Takeda (originally Shire). Pharmacology, dosing, evidence, scheduling rationale, and Dylan verdict (SKIP-FOR-NOW MEDIUM, with conditional flip to STRONG-CANDIDATE on formal ADHD or BED diagnosis) are identical. This file exists as a name-search stub for users who know the compound by the EU brand.

Ezetrol is the international (EU, Canada, Australia, etc.) brand name for the same active drug as Zetia in the US — ezetimibe, a selective NPC1L1 inhibitor for cholesterol absorption blockade. All research, dosing, and clinical content already documented in `ezetimibe.md`.

This is the same compound as rhodiola.md. The "3:1" notation refers to a herb-to-extract concentration ratio (3 g raw root yields 1 g extract) that does NOT specify rosavin or salidroside content. For meaningful pharmacology, prefer SHR-5 or rosavin-standardized extracts. See parent file rhodiola.md for full analysis.